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Abstract
Ryanodine receptor isoform-1 (RyR1) is a major calcium channel in skeletal muscle important for excitation-contraction
coupling. Mutations in the RYR1 gene yield RyR1 protein dysfunction that manifests clinically as RYR1-related congenital
myopathies (RYR1-RM) and/or malignant hyperthermia susceptibility (MHS). Individuals with RYR1-RM and/or MHS
exhibit varying symptoms and severity. The symptoms impair quality of life and put patients at risk for early mortality,
yet the cause of varying severity is not well understood. Currently, there is no Food and Drug Administration (FDA)
approved treatment for RYR1-RM. Discovery of effective treatments is therefore critical, requiring knowledge of the
RyR1 pathway. The purpose of this review is to compile work published to date on the RyR1 pathway and to
implicate potential regions as targets for treatment. The RyR1 pathway is comprised of protein-protein
interactions, protein-ligand interactions, and post-translational modifications, creating an activation/regulatory
macromolecular complex. Given the complexity of this pathway, we divided these interactions and modifications
into six regulatory groups. Three of several RyR1 interacting proteins, FK506-binding protein 12 (FKBP12), triadin,
and calmodulin, were identified as playing important roles across all groups and may serve as promising target
sites for treatment. Also, variability in disease severity may be influenced by prolongation or hyperactivity of post-
translational modifications resulting from RyR1 dysfunction.
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Introduction
Ryanodine receptor 1-related myopathies (RyR1-RM)
comprise the most common non-dystrophic congenital
myopathy, with a prevalence of approximately 1/90,000
in the United States [2, 83]. Causative mutations in the
gene (RYR1), which encode the major sarcoplasmic
reticulum calcium release channel of skeletal muscle
(RyR1), have been found in several myopathy subtypes.
Although dominantly inherited central core disease
(CCD, MIM# 11700) and recessively inherited multi-
minicore disease (MmD) are the most commonly associ-
ated myopathies caused by mutations in RYR1, mutations
have also been identified in cases of centronuclear myop-
athy (CNM), congenital fiber-type disproportion (CFTD),
and King Denborough syndrome [41, 47, 85] These
mutations result in constant calcium leak at rest, de-
fective excitation-contraction coupling, and increased
mitochondrial oxidative stress [48, 83]. Malignant
hyperthermia susceptibility (MHS) trait, a dominantly
inherited, severe pharmacogenetic reaction to volatile
anesthetics and muscle relaxants, is an allelic condition
(MIM# 145600) [85].
The clinical spectrum of RYR1-RM is quite broad.
Even within CCD, symptoms may range from very mild
to severe. Individuals with CCD typically present with
proximal muscle weakness of the hip girdle, hypotonia,
mild facial weakness, joint laxity and/or mild contrac-
tures, and/or orthopedic complications such as scoliosis
[22, 83, 85]. Both hip girdle weakness due to fetal hypo-
tonia and acetabular dysplasia contribute to congenital hip
dislocation, which is also observed in CCD [22, 40, 45]. A
more severe form of CCD is CCD-associated fetal akin-
esia. Related symptoms include severe hypotonia, arthro-
gryposis, skeletal deformities, kyphoscoliosis, and failure
to thrive. In some cases, individuals survive birth, and
present with strabismus and bilateral ptosis [118]. Individ-
uals with MmD present with moderate to severe
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symptoms, such as proximal and distal weakness, hypo-
tonia, a combination of contractures and/or laxity, pro-
gressive scoliosis, and, in some cases, bulbar weakness
and/or external ophthalmoplegia [158]. Individuals with
CNM are similar to MmD, but have more severe symp-
toms initially with improvement overtime. They often
present with proximal muscle weakness, ophthalmoplegia,
facial weakness, and respiratory impairment [82]. Symp-
toms associated with CFTD may include skeletal muscle
wasting and weakness, hypotonia, ophthalmoplegia, pto-
sis, respiratory impairment, congenital hip dislocations,
joint contractures, foot deformities, and kyphoscoliosis
[29, 37]. In rare recessive cases, congenital onset is very
severe with respiratory failure requiring ventilation [21,
22, 83, 85, 158]. The phenotype is complicated by sev-
eral symptoms and may include myalgia, axial weakness,
and fatigability [46, 80, 83]. Severity may vary within the
family [83] with some individuals presenting with myop-
athy and MHS and others presenting with only MHS [85].
The defining histopathological feature on muscle bi-
opsy is the presence of a single, central amorphous core
extending longitudinally along the muscle fiber in the
case of CCD or multiple smaller cores in one fiber
(MmD), which in both cases are likely due to reduced
mitochondrial oxidative enzyme activity as a result of
mitochondrial deficiency or depletion [83, 85]. Fiber type
predominance is another histological finding in RYR-RM
[81, 158]. Fiber type transformation has been shown to
result from mitochondrial activity relative to nitric oxide.
As mentioned below in the nitrosylation section of
group 5, nitric oxide binds to cytochrome C oxidase of
the electron transport chain and inhibits mitochondrial
respiration. This phenomenon has been shown in adi-
pose tissue and skeletal muscle and is dependent on
peroxisome proliferator-activated receptor gamma coac-
tivator 1-alpha (PGC-1α). PGC-1α regulates muscle fiber
type generation, favoring type I fibers. Additionally,
PGC-1α overexpression in mouse skeletal muscle results
in increased β-oxidation of fatty acids, increased muscle
glucose uptake, and overexpression of proteins involved
in fat oxidation and glucose transport [134]. We may
better understand type I fiber predominance, and pos-
sibly uniformity, by studying PGC-1α in RYR1-RM skel-
etal muscle. PGC-1α levels may be affected greatly due
to skeletal muscle fatty infiltration and mitochondrial
dysfunction in RYR1-RM.
Type I fiber predominance and hypotrophy are identi-
fied in most cases [81, 85, 154, 158] In some cases
(namely C-terminal RYR1 mutations), there is also type
1 fiber uniformity without structural changes in over
99 % of the type 1 muscle fibers. This is very similar to
congenital neuromuscular disease with uniform type 1
fiber (CNMU1), and, in this disease, ophthalmoplegia is
considered to be an important clinical manifestation
[125, 126]. This may also be true in RYR1-RM where
type 1 fibers are uniform in cases with ophthalmoplegia.
On the other hand, cores may be absent in CNM and
CFTD, where the predominant features are central nu-
cleation and fiber-type disproportion where type 2 fibers
are at least 25 % larger than type 1 fibers [154], as their
names suggest. Fatty replacement, fibrosis, and/or nuclear
internalization may also be present [22, 83].
In some cases, nemaline rods and cores coexist with
myofibrillar disorganization. Patients with rods and
cores are considered to have central core/rod disease
(CCRD). Interestingly, instead of leaky RyR1 channels as
noted in CCD, individuals with CCRD present with ex-
cess ryanodine receptors in the central cores [127]. In
the recessive form of CCD, MmD, there is a depletion of
the RyR1 protein [158].
Although RyR1 is a simple transmembrane protein
(homotetrameric), the variation in symptomology in
RYR1-RM suggests there is more to this protein and its
function, including modifying factors [83, 158]. When
scanning the literature, each article unveils small pieces
to a bigger puzzle. This review combines several pieces
to gain a more complete understanding of RyR1. Under-
standing RyR1 is critical for treatment development in
RYR1-RM, especially given the lack of FDA approved
treatment to date. Combined, the literature elucidates
RyR1 as a simple protein with a complex pathway due to
its tight regulation of ortho- and retrograde calcium flux
by several factors including proteins, post-translational
modifications, and ligands. Additionally, this paper high-
lights what is known about RyR1 mutations, the affected
interaction sites, possible regulatory functions disrupted,
and translation into the diseased state. These compiled
results suggest target sites and regulatory complexes for
potential therapies.
RyR1 Structure
RyR1 is a major Ca++ ion channel in skeletal muscle. It
is a six transmembrane (S1–S6) homotetrameric protein
located in the sarcoplasmic reticulum and functions to
release Ca++ from the SR to produce skeletal muscle
contraction. The 3-dimensional structure of RyR1 was
recently unveiled by Zalk et al. (2015). The transmem-
brane region of RyR1 is comprised of two domains
including the pseudo voltage sensor domain and the
pore-forming domain. S1–S4 helices form the pseudo
voltage sensor domains interface with the pore-forming
domain of the adjacent RyR1 subunit. S5–S6 helices and
the p-segment create the pore-forming domain of RyR1.
Similar to other six transmembrane ion channels, RyR1
also has a conserved glycine (aa4934). This region in the
other ion channels serves as glycine hinges, allowing for
the reorientation of the pore-forming regions in the ion
channels. The same may hold true for RyR1. The P-
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segment, an extended peptide, is thought to contribute to
the high conductance of RyR1 as it has an acidic predom-
inance due to anionic amino acid residues. This is also the
case for the cytosolic region of the S6 helix [156].
RyR1 Pathway
There are several mutations in various RyR1-protein
interaction and post-translational modification sites that
result in autosomal dominant and recessive myopathies.
RYR1 mutations for CCD and MH are primarily located
in the hot spots of RyR1. The hotspots, also referred to
as domains 1–3 (D1, D2, and D3), include N-terminal
residues 1–614 (sarcoplasm), central domain residues
2163–2458 (sarcoplasm), and C-terminal residues 4136–
4973 (Pore-forming, SR lumen, and membrane) [155]. MH,
however, does not have corresponding mutations in the
pore-forming regions [146]. CCD and MH mutations result
in leaky RyR1 channels. MmD, CNM, and CFTD mutations
result in reduced RyR1 protein expression [10, 82]. CCRD,
though uncommon, results in excess RyR1 protein [127].
The corresponding mutations for the recessive RYR1-RM
are located across the gene [130, 144, 159].
The RyR1 pathway is comprised of several RyR1
protein-protein interactions, protein-ligand interactions,
and post-translational modifications that comprise an
activation/regulatory macromolecular complex. Given
the complexity of this pathway, we have divided these
interactions and modifications into six regulatory
groups. Namely, group 1 responds to action potentials
(initiation of Ca++ release) and changes in sarcoplasmic
and sarcoplasmic reticulum [Ca++]. Groups 2 and 3 re-
spond to changes in SR [Ca++]. Group 4 responds to
changes in cAMP (elevated due to ACh release), Group
5 responds to changes in muscle O2 and glutathione ra-
tio (GSH/GSSG), and group 6 seems to respond to
sarcoplasmic [Ca++]. Each group functions to open and
close the RyR1 channel and will be discussed in detail.
Disease causing mutations are outlined at the end of
each applicable group.
Review of 6 Regulatory Groups
 Group 1 contributes to orthograde signaling
where EC coupling is initiated in response to
neuromuscular stimulation.
 Group 2 includes RyR1 interdomain interactions
that contribute to the opening and closing of the
channel externally (group 1) and internally (group 3).
 Group 3 regulates retrograde signaling depending on
SR [Ca++] and calsequestrin (CSQ) phosphorylation/
dephosphorylation states.
 Group 4, like group 1, is activated based on
neuromuscular stimulation with the exception
that group 1 responds to a resulting action potential,
and group 4 responds to resulting cAMP production.
 Group 5 is comprised of post-translational modifica-
tions (nitrosylation, oxidation, glutathionylation,
and palmitoylation) of which all act on RyR1
cysteine residues regulating the key proteins in the
other groups.
 Group 6 includes extracellular ligands that when
bound stabilize the closed-state of non-voltage
activated RyR1 channels until the RYR1 open
state is activated by PKA-dependent phosphorylation
of RyR1 (group 4). Ca++ has both activation and
inhibitory sites on RyR1 affecting Calmodulin
(CaM)-binding (group 2).
Group 1
Group 1 (Fig. 1a) responds to neuromuscular action po-
tentials that initiate excitation-contraction coupling.
RyR1 interactions in group 1 are located in the sarco-
plasm and are comprised of RyR1, DHPR, FKBP12, and
triadin proteins. DHPR-RyR1, FKBP12-RyR1, and
triadin-RyR1 interactions potentiate the open probability
of RyR1 with voltage-gated activation. This group also
responds to Ca++ and is thus regulated by changes in
sarcoplasmic [Ca++]. Initially, the DHPR undergoes a
conformational change, which then activates RyR1. Simi-
larly, RyR1 undergoes a conformational change resulting
in RyR1 interdomain interaction (discussed later)
followed by calcium release that leads to excitation-
contraction coupling. FKBP12 and triadin are important
in this group for regulating the opening and closing of
RyR1 following DHPR activation. In taking a closer look
at these proteins, we are able to better understand their
interaction and how they regulate the RyR1 channel.
DHPR
The dihydropyridine receptor (DHPR), also referred to as
CaV1.1, serves as a voltage-gated L-type calcium channel
as well as a voltage sensor that is essential for excitation-
contraction (EC) coupling achieved via DHPR-RyR1 inter-
action in skeletal muscle [31, 32, 99]. DHPR serves as a
voltage sensor to neuromuscular excitation for the initi-
ation of EC coupling (orthograde signaling), and serves as
a L-type Ca++ channel for retrograde signaling [99].
DHPRs are located in the transverse tubule of skeletal
muscle clustered in tetrads. Each tetrad interacts with
every other RyR1 homotetramer [116], and is activated by
sarcolemmal depolarization [31, 116]. Once activated,
DHPRs undergo a conformational change that leads to
RyR1-mediated Ca++ release [105, 116].
Amino acids 1635–2636 of RyR1 are required for
orthograde and retrograde signaling, whereas amino
acids 2659–3720 contribute to retrograde signaling only
[98, 129]. Thr671-Lys690 region of the DHPR α1 II-III
loop promotes orthograde signaling and directly binds
to and induces the open state of RyR1.
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Fig. 1 (See legend on next page.)
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DHPRs are comprised of five subunits including α1,
α2, β, γ, and δ [32, 107] where the β and α1 subunits
have been shown to be key players in excitation-
contraction coupling [105, 112]. β and α1 subunits dir-
ectly interact with RyR1 [35, 105, 112].
The β subunit guanylate kinase domain binds to the
II-III loop of the α1 subunit and its C-terminus binds to
RyR1 residues K3494-R3502 [35, 112]. Rebbeck [112] the β
subunit functions to ensure correct positioning of the
DHPR to allow α1 subunit coupling to RyR1 and main-
tains the open state of RyR1 in the presence of Ca++ and
ATP. However, physiologic levels of Mg2+ inhibit β sub-
unit activity [112], but the effect of Mg2+ is relieved by
activation of the RyR1 voltage sensor, DHPR, where
magnesium is disassociated from the inhibitory site on
RyR1 [86, 124]. It has been shown that Ca++ and Mg+
+compete for the same binding site on RyR1. Unlike Mg2
+, Ca++ reinforces the open state of RyR1 [86].
The II-III loop of the α1 subunit is critical for ortho-
grade signaling to RyR1 in response to DHPR voltage-
gated activation [98] and also enhances DHPR function
via retrograde signaling from RyR1 to the DHPR [97, 104].
Orthograde signaling results in the release of Ca++ from the
sarcoplasmic reticulum through the RyR1 ion channel. In
contrast, RyR1-DHPR retrograde signaling has been sug-
gested to promote inactivation of the DHPR “to limit SR
Ca++ release and store depletion.” This hypothesis is based
on the Y522S mutation, in myotubes of RyR1 knock-in
mice, altering voltage-dependent inactivation of the DHPR
where the voltage-dependent inactivation of DHPR-
triggered Ca++ release was shifted to more negative holding
potentials. In doing so, the voltage threshold for Ca++ re-
lease is lowered, limiting Ca++ release. Heat also results in
this shift. Given the reduced Ca++ release, it is proposed
that steady state DHPR-inactivation may be a compensa-
tory mechanism used to counteract excessive Ca++ leak and
SR Ca++ store depletion. In cases where this compensatory
mechanism did not exist, the mutant (Y522S) myotubes ex-
hibited Ca++ leak and SR Ca++ store depletion [6]. Recently,
DHPR-inactivation, due to prolonged depolarization, as the
primary cause of limiting excessive Ca++ leak and SR Ca++
store depletion has been challenged, and instead is believed
to primarily be due to SR Ca++ store depletion triggering
steady-state DHPR-inactivation [93]. Although controver-
sial, investigating these mechanisms in greater detail to
identify future paths toward treatment is essential.
FKBP12
FK506-binding protein 12 (FKBP12) is encoded by the
calstabin-1 gene and is located in the sarcoplasm of
skeletal muscle. There are four FKBP12 subunits that
bind to the homotetrameric RyR1 protein in a 1:1
manner [151]. Until recently, FKBP12 has been shown
to bind to RyR1 at aa sites 2461 and 2462 [11, 61, 65]. Fur-
ther exploration of the FKBP binding sites on RyR1 re-
vealed that FKBP interacts with the N-terminal (76–619)
and central (2157–2777) domains of RyR1 [65]. More
specifically, FKBP binds at aa sites 619, 2157, 2341,
and 2502.
The interaction between FKBP12 and RyR1 alters
DHPR-RyR1 functional interaction [11]. FKBP12 pre-
vents leaky RYR1 signaling under sub-optimal ligand
concentratations, and therefore serves as a molecular
“gradient reader.” (Uniprot) Therefore, FKBPs are sug-
gested to have “a stabilizing effect on RyR channel function
by lowering open probability and preventing subconduc-
tance state gating,” which leads to “fewer leaky RyR chan-
nels and fewer aberrant Ca++ release events (Venturi et al.
2014).” Originally, FKBP12 was thought to stabilize RyR1
in skeletal muscle whereas FKBP12.6 stabilized RyR2 in
cardiac cells [62]. Additional studies showed RyR2 likely
undergoes dual modulation by FKBP12 and 12.6, such that
FKBP12.6 acts as an FKBP12 antagonist indirectly redu-
cing RyR2 open probability and SR Ca++ release. Since
(See figure on previous page.)
Fig. 1 a Group 1. 1) RyR1 open (voltage-gated): RyR1 activation in response to DHPR activation by acetylcholine (ACh) release at the
neuromuscular junction in skeletal muscle 2) RyR1 closed: no neuromuscular-stimulated ACh release. b Group 2. 1) RyR1 open: No interdomain
interaction (unzipped) with bound ApoCaM in response to RyR1 activation preceded by DHPR activation resulting in high sarcoplasmic Ca2+
2) RyR1 closed: bound Ca2+-Cam at high [Ca2+] resulting in interdomain interaction (zipped) and high sarcoplasmic reticulum (SR) Ca2+. c
Group 3. 1) RyR1 open: RyR1-triadin interaction due to triadin-calsequestrin (CSQ) interaction at high Ca2+ bound CSQ resulting in high
sarcoplasmic Ca2+ 2) RyR1 closed: RyR1-junctin interaction due to junctin-CSQ interaction at low Ca2+ bound CSQ in phosphorylated state resulting
in high SR Ca2+. d Group 4. 1) RyR1 open: RyR1 and Gm phosphorylation by PKA due to high [cAMP] resulting in high sarcoplasmic Ca2+ 2) RyR1
closed: RyR1 dephosphorylation by PP1 due to low [cAMP] resulting in high SR Ca2+. e Group 5. S-nitrosylation. 1) RyR1 open: nitrosylation of RyR1
cysteine residues by nitric oxide-glutathione reaction in response to physiologic p(O2) resulting in high sarcoplasmic Ca
2+2) RyR1 open: nitrosylation
of RyR1 by nitric oxide overrides Ca-CaM inhibitory effect resulting in high sarcoplasmic Ca2+ S-oxidation. 1) RyR1 open: oxidation of RyR1 cysteine
residues by reactive oxygen species reaction in response to increased physiologic p(O2) resulting in high sarcoplasmic Ca
2+ 2) RyR1 closed: no RyR1
oxidation at low physiologic p(O2) with bound Ca
2+-CaM resulting in high SR Ca2+ S-glutathionylation. 1) RyR1 open: initial increase in reduced
glutathione (GSH) stimulating glutathionylation of RyR1 cysteine residues by GSH, in turn, decreasing the GSH:GSSG and reducing RyR1 sensitivity to
Mg2+ inhibition resulting in high sarcoplasmic Ca2+ 2) RyR1 closed: no glutathionylation until GSH:GSSG ratio is restored resulting in high SR
Ca2+S-palmitoylation. 1) RyR1 open: palmitoylation of RyR1 cysteine residues by the fatty acid palmitoyl-CoA resulting in high sarcoplasmic Ca2+2)
RyR1 closed: no palmitoylation resulting in high SR Ca2+. f Group 6. 1) RyR1 open: RyR1-ligand (Ca2+and ATP) binding activation resulting in high
sarcoplasmic Ca2+ 2) RyR1 closed: RyR1-ligand (Ca2+ and Mg2+) binding deactivation resulting in high SR Ca2+
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FKBP12.6 affects skeletal muscle function, dual modula-
tion of RyR1 is also thought to occur [147].
The role of FKBP12 in the RyR1 EC-coupling pathway
is controversial (Avila et al. 2003). Researchers initially
demonstrated FKBP12 functions to close the RyR1 chan-
nel, but later showed FKBP12 also potentiates the RyR1
open state. According to Gaburjakova et al. (2001), the
increased RyR1 gating frequency in the absence of
FKBP12 suggests that FKBP12 functions to stabilize
RyR1 in its open and closed states.
In group 1, the interaction between DHPR and RyR1
is modulated by FKBP12 [98] such that FKBP12 strongly
potentiates the open state of RyR1 when RyR1 is bound
to the Thr671-Lys690 region of the DHPR II-III loop
[100]. In support, when FKBP12 was depleted, this re-
sulted in obliteration of the open state of RyR1 following
DHPR activation [100]. Not only does FKBP12 directly
interact with RyR1 in the presence of DHPR activation,
but it has also been identified in a group including RyR1,
protein kinase A (PKA), phosphodiesterase 4D3 (PDE4D3),
and protein phosphatase 1 (PP1). Within this group,
FKBP12 functions to close the RyR1 channel, which is
discussed in more detail later.
Given that FKBP12 plays a role in RyR1 open and
closed states, future studies are required to determine if
FKBP12 function changes depending on the RyR1 aa
position to which FKBP12 binds. It may also be import-
ant for treatment purposes. For example, rycals, drugs
that enhance FKBP12 binding to RyR1 [20], may be an
effective treatment in the RYR1-RM population with
mutations that negatively affect FKBP12 interaction with
RyR1 and result in RYR1-RM. For this reason, we are
currently performing a pre-clinical study testing the ef-
fect of Rycals on RyR1 function in muscle fibers biopsied
from patients with RYR1-RM in collaboration with
Marks and colleagues (unpublished data).
Triadin
FKBP12 modulation of RyR1 activity is proposed to me-
diate the regulatory role of triadin on RyR1 activity [24].
Triadin is a junctional SR membrane glycoprotein that
has been shown to interact with DHPR and RyR1 in
the sarcoplasm [58, 68] supporting triadin playing a
role in orthograde coupling. Disruption in RyR1 and
triadin binding reduces orthograde signaling. However,
it does not affect retrograde signaling between RyR1
and DHPR [67].
When the interaction between sarcoplasmic RyR1 and
triadin is disrupted, this results in RyR1 channel inhib-
ition. Amino acids 18–46 of triadin interact with RyR1
in the sarcoplasm at low Ca++ levels, whereas this bind-
ing is inhibited at high Ca++ levels. The prevention of
amino acids 2–17 of triadin from binding to RyR1 by
use of antibodies does affect RyR1 channel function,
thereby resulting in a reduced rate of SR Ca++ release
and decreased open probability of RyR1 [68].
Although triadin is not well understood, it is thought
to regulate RyR1-DHPR interaction, and in turn, modu-
late EC coupling [53]. A number of studies have identi-
fied that triadin is “primarily a negative regulator of
RyR1 [52]” [68, 70, 103, 131]. One study showed that
amino acids 664 to 799 of DHPR alpha 1 subunit bind
to triadin primarily at amino acids 68–278 [58]. Al-
though triadin interacts with DHPR in the sarcoplasm,
EC coupling and RyR1 channel regulation were not pre-
vented in triadin null mice compared to wild type [131],
yet, a significant reduction in muscle strength was
shown in triadin null mice [101]. Interestingly, Shen et
al. (2007) demonstrated little to no difference in force
generation between wild type and triadin null mice in
response to electrical stimulation. It is important to note
that both Shen et al. (2007) and Oddoux et al. (2009)
used triadin null mice, but electrically stimulated differ-
ent muscles including the lumbricals and flexor digi-
torum of the hindlimb, respectively. These muscles may
be affected differently in triadin null mice, and so
affected muscle groups should be determined.
Despite no change in force generation, Shen et al.
(2007) demonstrated electrical stimulation still resulted
in a lower magnitude of Ca++ transients. Similar findings
were shown in isolated myotubes from the same mice as
well as a significant increase in resting myoplasmic Ca++
[131]. In support, Eltit et al. (2010) demonstrated chron-
ically elevated resting myoplasmic Ca++ due to FKBP12-
RyR1 dysfunction and SR store-operated Ca++ entry
[52, 53], suggesting increased basal RyR1 activity in
triadin null myotubes isolated from skeletal muscle of
mice. Additionally, Oddoux et al. (2009) revealed a
reduction of SR Ca++. Together, the results reveal that
triadin ablation affects resting Ca++ levels such that there
is an increase in myoplasmic Ca++ and a reduction in SR
Ca++, supporting a lower magnitude of Ca++ transients in
response to electrical stimulation. Eltit et al. (2011) also
showed that triadin null mice result in no significant dis-
ruption of EC coupling. However, further kinetic analysis,
in isolated myotubes, revealed that voltage-gated activa-
tion time for Ca++ release was slowed [53].
Given that triadin null mice presented with what ap-
pears to be a “normal” phenotype, it was suggested by
Shen et al. (2007) that the role triadin plays in muscle
function is minor or replaced with a compensatory
mechanism [131] Conversely, according to Oddoux et al.
(2009), a decrease in muscle strength in triadin null
mice, suggests triadin dysfunction may lead to the devel-
opment of a myopathy and is therefore essential for
skeletal muscle function. Since both authors make valid
points, whether or not the absence of triadin results in a
RyR1 myopathy has yet to be determined.
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Group 1 Pathomechanisms:
CCD/MH:Mutations in the RyR1 N-terminal and central
domains that disrupt FKBP12-RyR1 interaction are
proposed to result in MH [65, 104] or CCD/MH
[104]. V2461G and V2461I are RyR1 mutations that
disrupt FKBP12 binding. In skeletal myotubes expressing
these mutations, there was approximately a 50 %
reduction in voltage-gated Ca + release due to the
V2461G mutation compared to wild type. Myotubes
expressing the V2461I mutation resulted in the binding
of FKBP12.6 as opposed to FKBP12. In response, there
was a reduction in SR Ca++ release [11]. A study
performed by Galfre et al. (2013) identified three
FKBP12 sites that interact with RyR1. Mutations
introduced at any of these sites changed the function
of FKBP12 such that mutant FKBP12 (at sites Glu31,
Asp32, orTrp59) functioned as FKBP12.6, thereby ac-
tivating the RyR1 channel and resulting in Ca++re-
lease. Based upon the above results, FKBP12 should
be studied in more detail under different conditions.
CCRD: Similar to I4898T, a well known mutation
mentioned in group 3, the Y4796C mutation in RyR1 is
also suspected to interfere with the interaction between
RyR1 and triadin, but rather in the myoplasmic domain
instead of the SR luminal region. Patients with the
Y4796C mutation present with cores and rods on
muscle biopsy, and therefore have CCRD.
Consequently, there is increased rate of calcium leakage
from the SR [95]. Y4637A and Y4637I mutations, like
Y4796, also result in CCRD [90]. Amino acid 4637 is
located in the membranous region of the RyR1 C-
terminus. Similar to characteristics of the I4898T
mutation, resting calcium levels associated with T4637A
significantly increase and SR luminal Ca++ decreases.
However, instead of leaky RyR1 channels as noted in
CCD, individuals with the T4637A mutation present
with excess ryanodine receptors in the central cores
[127]. The T4637 pathomechanism may be the same for
the Y4796C mutation rather than an increased rate of
calcium leakage, but further research is needed.
CFTD: Mutations associated with autosomal recessive
myopathies often include a missense mutation along
with a null mutation, and sometimes a homozygous
missense mutation [10]. In a study with six patients
diagnosed with CFTD, each patient exhibited a
heterozygous missense mutation in addition a null
mutation [37]. RYR1 mutations resulting in CFTD
are linked to the RyR1-DHPR (α and β) binding sites.
Group 2
Group 2 (Fig. 1b) is located in the pore-forming region
of RyR1 and is comprised of RyR1 interdomain inter-
action and calmodulin (CaM). This group responds to
the activation of RyR1 by DHPR and is regulated by SR
Ca++. It has been suggested that RyR1 conformational
change in response to DHPR activation leads to RyR1 in-
trinsic modulation of the opening/closing of the RyR1
ion channel. This intrinsic modulation is based on inter-
domain interaction where the RyR1 central domain
(Leu2442-Pro2477) interacts with the RyR1 N-terminal do-
main [104]. This interdomain interaction is regulated by
CaM and Ca++ levels regulate the function of CaM.
RyR1 Interdomain interaction
Bannister et al. (2007) proposed the “domain switch” hy-
pothesis that reflects the structure-function relationship
between the interdomain interaction and RyR1 function.
The hypothesis states that “In the non-activated state,
the N-terminal and central domain make close contact
through several sub-domains: this ‘zipped’ state stabilizes
the closed state of the channel. Under normal stimulat-
ing conditions, the inter-domain contact is weakened
leading to an ‘unzipped’ state, which is recognized by
the channel as an activation signal.” Interestingly, MH
mutations have been shown to result in a partial un-
zipped state leading to “hyperactivation/hypersensitiza-
tion” of RyR1 [12].
Domain peptide 4 (DP4) is a synthetic peptide that
corresponds to Leu2442-Pro2477 of RyR1. When DP4 was
bound to the N-terminus of RyR1, this interaction re-
sulted in an “unzipped” state that led to activation of
ryanodine binding and SR Ca++ release [12]. Olojo et al.
(2011) determined how the interdomain interaction in-
fluences orthograde and retrograde signaling by using
DP4. The results showed enhanced RyR1 orthograde Ca
++ release without affecting the DHPR voltage sensor
and mediated retrograde signaling that results in a RyR1
open state [104]. In summary, the RyR1 conformational
change in response to DHPR activation results in the
“unzipped” state where the interdomain interaction is
weakened and is recognized by RyR1 as an activation
signal leading to the release of Ca++ [12]. Under normal
conditions, the central domain and N-terminus make
close contact maintaining the “zipped” state of RyR1
thereby stabilizing the RyR1 closed state [12].
Calmodulin
Under normal conditions, CaM disrupts the interdo-
main interaction [77]. CaM exists in two forms, with-
out Ca++ (apocalmodulin, apoCaM) and Ca++ bound
(Ca++-CaM). Both forms bind to RyR1 with Ca++-CaM
having a greater binding affinity [157]. ApoCaM
serves as an agonist resulting in the release of Ca++
at low sarcoplasmic [Ca++], whereas Ca++-CaM main-
tains the closed state of RyR1 at high sarcoplasmic
[Ca++] [64, 73, 77, 92, 157]. CaM levels increase as
sarcoplasmic Ca++ levels increase. More recently,
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researchers showed that activation of CaM results in
CaM Kinase II (CaMKII) activation, which, in turn,
phosphorylates RyR1, affecting skeletal muscle con-
tractility. In summary, Ca++-CaM binds to RyR1 on
the sarcoplasmic side inhibiting SR Ca++ release, and,
while bound, CAMKII phosphorylates RyR1 [64].
CAMKII, and as discussed later, PKA, both phosphor-
ylate RyR1 and are thus considered modulators of RyR1
activity. It is important to note that hyperphosphoryla-
tion of RyR1 by CAMKII or PKA results in FKBP12
disassociation, and consequently, a higher open prob-
ability of RyR1. Along this continuum, a higher RyR1
open probability due to hyperphosphorylation may affect
skeletal muscle contractility under resting conditions
where skeletal muscle contractility is decreased [64].
In 2002, O’Connell et al. demonstrated that the intro-
duction of CaM binding sites (3624 and 3620) in dyspedic
myotubes primarily regulates L-type channel currents for
retrograde signaling compared with EC coupling for
orthograde signaling [99]. The structure of CaM is com-
prised of two lobes, a N- and C-lobe where the C-lobe of
Ca++-CaM binds at RyR1 sites 3614–3643 [77] and the N-
lobe to 1975–1999. Both of these undergo interdomain
interaction [157]. Specifically, the interdomain interaction
includes disulfide bonds formed between cysteine residues
that include 3635, 2000, and 2401 [157] of adjacent RyR1
subunits within a tetramer. The ApoCaM-binding domain
of RyR1 (Lys3614-Asn3643) also interacts with RyR1 sites
Cys4114-Asn4142. When bound, this leads to Ca++ release
[63]. ApoCaM not only binds to aa 3614–3643, but also
aa 3625–3644 [117].
Although ApoCaM and Ca++-CaM have opposing func-
tions, both prevent oxidation-induced intersubunit cross-
linking where disulfide bonds are formed between each
RyR1 subunit leading to Ca++ release [72, 110]. Post-
translational modifications of RyR1, group 5, are discussed
later. It is postulated that CaM protects RyR1 from oxida-
tive stress associated with strenuous exercise [28, 73].
Conversely, oxidation of RyR1 prevents the binding of
CaM (both forms) to RyR1 at low [Ca++]. Nitric oxide
(NO), which plays a role in redox reactions involving
RyR1, not only blocks intersubunit disulfide bonds
formed by oxidation but also prevents the binding of
ApoCaM [72, 110]. These data suggest that NO regu-
lates oxidation and ApoCaM activity, both of which pro-
mote the RyR1 open state. The unaffected Ca++-CaM by
NO, when bound to RyR1, results in the RyR1 closed
state. The redox reactions are discussed later.
In the nitrosylation subsection, the literature demon-
strates NO has a high affinity for CaM such that CaM is
required for nitrosylation to occur. Ca++-CaM bound
RyR1 is unaffected at most sites, thereby protecting
RyR1 from oxidation. Further research is necessary to
determine what occurs in a hypernitrosylated state or
when mutations are present in the Ca++-CaM binding
site on RyR1. If such changes result in a myopathy or
malignant hyperthermia phenotype, this research would
open the door to potential treatments. Additionally,
given that CaM is not only required for nitrosylation,
but also activates downstream phosphorylation of RyR1,
it is important to determine whether hyperphosphoryla-
tion and hypernitrosylation occur simultaneously and
possibly contribute to disease severity.
Interestingly, increased levels of CaM not only activate
CAMKII, but also calcineurin. Calcineurin is a phos-
phatase responsible for skeletal muscle satellite cell
differentiation, which is important for skeletal muscle
fiber regeneration after injury and skeletal muscle hyper-
trophy [64, 145]. Activation of calcineurin primarily
influences slow twitch fiber hypertrophy. In mice, inhib-
ition of calcineurin resulted in marked inflammation,
fiber atrophy, presence of immature myotubes, and cal-
cification in regenerating muscle compared with controls
[122, 123]. Further research is required to understand
the role of calcinuerin in RYR1-RMs. Targeting calcine-
urin may be a potential therapeutic treatment.
Group 2 Pathomechanisms:
MH: When DP4 was isolated in skinned skeletal muscle
fibers, it enhanced ryanodine binding and sensitized the
release of SR Ca++ similar to what has been shown in
MH pathology. It is believed that MH results from the
disrupted interdomain interactions between DP4 and
the N-terminus of RyR1 that result in destabilization of
the RyR1 closed state [87].
MmD: Mutations in RyR1 that manifest as MmD
are dispersed throughout RyR1 primarily outside the
hot spot regions. RyR1 mutations P3527S and V4849I
cause an increase in sarcoplasmic resting Ca++ without
depleting SR Ca++ stores [143, 144, 159]. V4849I is an
interesting mutation linked to autosomal recessive
CCD, which presents as MmD [59].
The aforementioned mutations are located in the
S100A1 and CaM binding sites. Researchers are
continously learning more about S100A1, but it is
believed that this S100A1 is responsible for linking
RyR1 subunits. S100A1 is considered one of the most
important ligands in cardiac muscle, possibly skeletal
muscle, and is also responsible for Ca++ release at low
[Ca++]. A single site on RyR1 binds both S100A1 and
Ca++-Cam. The release of Ca++ at low [Ca++] contributes
to muscle twitches, however, the same site is critical for
inhibiting Ca++ release during “repeated or sustained
activation by binding Ca++-CaM at higher [Ca++].
In this way, Ca++ is able to slow energy expenditure
later in contraction [92, 148]. Other RyR1 mutations,
R109W (also P109W) and M485W, occur simultaneously
and some are intronic variants such as homozygous
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 8 of 20
14646 splicing variant resulting in a reduced number
of RyR1 [143, 144, 159]. MmD patients with these
mutations clinically present with ophthalmoplegia
and muscle weakness.
Ophthalmoplegia, in this patient population, is thought
to be due to the absence of RyR3 compensation [159].
In support, results reported by Perez et al. (2005)
suggest RyR1 and RyR3 together regulate skeletal
muscle Ca++. Ophthalmoplegia is also suspected to
be mutation specific or caused by mitochondrial
dysfunction [128, 130]. Causal RYR1 mutations are
located outside the hotspot regions or include a
malignant hyperthermia causing mutation accompanied
by another mutation outside the hotspot regions. Two
known mutation combinations include R3772W +
E989G and R3772W +H283R. A previously reported
R3772Q mutation caused a more severe phenotype
including ptosis, facial weakness, myopathy, and MHS.
MRI pathophysiological findings potentially responsible
for ophthalmoplegia, ptosis, and facial weakness include
thin hypoplastic intraorbital motor cranial nerves in
addition to hypoplasia of the extraocular muscles.
Interestingly, the optic nerve remained healthy and
intact [130]. Given the eye is a high-energy demand
organ, the extraocular muscles are comprised of several
mitochondria. However, chronic oxidative damage results
in mitochondrial instability yielding mitochondrial
damage. Mitochondrial dysfunction, increased oxidative
stress, and increased apoptosis are common causes of
ophthalmologic disorders in the aging population [128].
Although mitochondrial-related extraocular muscle
dysfunction has not been shown in RYR1-RM, this
pathomechanism may be worth assessing in this
patient population.
CNM: RyR1 mutations that manifest as CNM occur in
DHPR, CaM, and sometimes the triadin binding sites
disrupting interdomain interaction [3]. RyR1-CaM
interaction can be disrupted in an environment with
high oxidant concentrations [110]. Associated mutations
include Glu1909GlyfsX39, Met3081Thr, Val4842Met,
10348-6C >G (intronic), Ser1342Gly, Thr2787Ser, and
3381 + 1 G > A (intronic). To achieve protein reduction,
it is suggested that the aforementioned mutations coexist
with the intronic mutation 10348-6C >G, which further
results in the production of another mutation,
His3449ins33fsX54 [82, 154].
Group 3
Group 3 (Fig. 1c) is located in the SR and is com-
prised of RyR1, CSQ, triadin, and junctin. This group
responds to the RyR1 interdomain interaction and is
regulated by SR Ca++. In group 3, CSQ seems to be
the primary protein of interest for RyR1 channel ac-
tivity because it indirectly regulates RyR1 open and
closed states depending on SR [Ca++]. CSQ, in its
phosphorylated and dephosphorylated states, regulates
RyR1 channel activity through its interaction with
junctin and triadin. The phosphorylated and dephos-
phorylated states of CSQ seem to be a regulatory
mechanism of the CSQ/junctin/triadin complex, and
the CSQ/junctin/triadin complex regulates RyR1 activ-
ity from the SR.
Triadin seems to be the key communicator between
orthograde and retrograde signaling following voltage-
gated activation of RyR1. Like FKBP12, it functions to
potentiate both the open and closed states of RyR1. Triadin
may also be a target for potential treatment. In group 1,
FKBP12.6 restored resting Ca++ levels by acting directly on
RyR1. Boncompagni showed that the SR luminal content
and cisternae volume were significantly altered in triadin
null mice [24]. How FKBP12.6 affects SR content while re-
storing resting levels is still to be determined. More studies
are required to focus on the mechanisms of action between
groups 1 and 3 as well as the pathomechanisms that result
from RyR1 mutations that interfere with sarcoplasmic and
SR luminal triadin binding sites.
CSQ
CSQ is a Ca++ storage glycoprotein located in the lumen
of the SR, which functions to lower the amount of free
Ca++ in the SR [79, 132, 142]. More recently, studies
have shown that CSQ is not only a storage protein. CSQ
also modulates RyR1 channel activity [132] and is pri-
marily located in close proximity to RyR1 [142]. Previous
research has shown that the amount of Ca++ released
from the SR is dependent on the amount of Ca++ bound
to CSQ [79]. When CSQ is partially bound, small
amounts of Ca++ are released at a high rate constant,
whereas when fully bound, Ca++ is released at a slow
rate constant [79]. In support, CSQ has been shown to
have a controlled inhibitory effect on RyR. In the
absence of CSQ, Ca++ release increased by 10 fold. This
effect was reversed after reintroducing CSQ [15]. Specific-
ally, the intraluminal phosphorylation/dephosphoryla-
tion of CSQ controlled RyR1 channel activity in the
presence of Ca++. When CSQ is dephosphorylated, Ca+
+is released from the SR, but when phosphorylated,
Ca++-bound CSQ has no effect on RyR1 [142].
It is important to note that CSQ does not directly
interact with RyR1. Rather, it interacts indirectly through
junctin and triadin [17]. Using a DCAM probe and elec-
tron microscopy, Ikemoto et al. (1989) showed Ca++
bound CSQ undergoes a conformational change, subse-
quently binding to junctional face membrane (jfm) pro-
teins later identified as junctin and triadin [17, 103]. It
was also demonstrated that conformational changes in
CSQ were coupled to conformational changes in RyR1; a
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conformational change in one was transmitted to the
other [142].
Junctin and triadin are transmembrane anchoring pro-
teins that form a stable quaternary group, including
RyR1, junctin, triadin, and CSQ. CSQ binds to junctin
and triadin under low Ca++ concentrations resulting in
the closed state of RyR1 [152]. Beard et al. (2008) dem-
onstrated that when CSQ is phosphorylated under low
SR luminal Ca++ concentrations, CSQ binds to junctin
only. This phosphorylated state of CSQ does not disrupt
the ability of CSQ to maintain the closed state of RyR1
[16]. Rather, it enhances the Ca++ binding affinity to
CSQ [17]. These results suggest that the inhibitory effect
of CSQ on RyR1 activity is mediated by junctin when
CSQ is in its phosphorylated state under low Ca++ con-
centrations [17]. Under physiological conditions of Ca++,
neither the phosphorylated nor the dephosphorylated
state affects the coupling of CSQ, junctin, and triadin
[16]. CSQ, in its dephosphorylated state under low SR
Ca++ conditions, binds only to triadin, in turn activating
ryanodine receptors. High luminal Ca++, on the other
hand, results in dissociation of the CSQ, triadin, and
junctin group [16]. Whether CSQ has an inhibitory [13,
14, 150] or activation [84, 102] effect on RyR1 has been
controversial.
In summary, CSQ and RyR1 have an indirect relation-
ship by way of triadin and junctin. This relationship
appears to depend on SR luminal [Ca++] as well as phos-
phorylation/dephosphorylation mechanisms. Low SR
luminal Ca++ promotes the binding of CSQ to junctin
and triadin. This results in the RyR1 closed state. The
binding of CSQ to junctin and triadin changes when
phosphorylation and dephosphorylation occur. Low SR
luminal Ca++ with CSQ phosphorylation still results in
the binding of CSQ to junctin only with no RyR1 activ-
ity. However, in its dephosphorylated state, CSQ binds
to triadin only and this interaction leads to RyR1 activation
(Fig. 1c). This RyR1 activation is inhibited by ryanodine
binding and cannot be reversed with dephosphorylated
CSQ. Since CSQ does not bind to triadin and junctin when
SR luminal Ca++ is high, based on current knowledge,
CSQ only communicates with RyR1 when SR luminal
Ca++ levels are low.
Triadin
In group 1, triadin was shown to bind to RyR1 and
DHPR on the sarcoplasmic side potentiating voltage-
gated RyR1 Ca++ release. Triadin also interacts with
RyR1 and CSQ in the SR lumen (group 3) in a Ca++
dependent manner serving as a linker protein between
RyR1 and CSQ [69, 119]. The sarcoplasmic region of
RyR1 and triadin become disassociated when the SR
luminal binding of these proteins are disrupted, but do
not affect RyR1 channel function [67]. Beard [18] based
on these results, SR Ca++ and group 3 seem to regulate
the function of triadin in group 1.
Three regions of triadin are responsible for its
localization at the membrane. These regions include the
targeting region (TR) 1 (18–47, sarcoplasmic), TR2
(106–214), and TR3 (233–440, 441–729). At least two of
these three regions are required for correct localization
in the membrane. Binding regions for RyR1 have been
identified in TR3, and the same is true for CSQ [30].
Specifically, triadin binds to the SR luminal side of RyR1
at amino acids D4907, E4908, and D4878 [89]. CSQ ap-
pears to be associated with triadin stabilization (reduced
mobility) in the SR membrane, and more importantly, a
key component for the formation of a stable group
between triadin and RyR1 [120].
Unlike the effect of triadin on RyR1 in group 1, triadin
in group 3 functions to close the RyR1 channel while en-
hancing the binding affinity of ryanodine to RyR1 [67].
Ryanodine binding is used to study Ca++ binding affinity
because ryanodine binding is Ca++ dependent. “Low af-
finity Ca++ binding sites resulted in inhibition of ryano-
dine binding and Ca++ release from isolated SR vesicles.”
[71] Ohkura et al. (1998) showed that depletion of
triadin increases ryanodine binding, but when available,
triadin functions to inhibit ryanodine binding to the SR
and maintain the closed state of RYR1. The effect of
triadin on ryanodine binding is the same even when
ryanodine binding is potentiated by CSQ [103].
Wei et al. [153] demonstrated that when triadin and
junctin are exposed to RyR1 independently, the open
state of RyR1 is enhanced. Once CSQ was added to each
solution, only the RyR1/junctin interaction led to a
reduction in RyR1 activity when the SR luminal Ca++
was lowered [18].
Junctin
Junctin, like triadin, is a transmembrane protein that
binds to RyR1 and CSQ. Unlike triadin, junctin only
binds to the luminal domain of RyR1. Junctin is believed
to play a more critical role in maintaining the SR Ca++
store and CSQ/RyR1 signaling in myotubes (Boncompagni
et al. 2012-refs 38 and 39). Boncompagni et al. (2012)
studied the function of triadin and junctin in Ca++ homeo-
stasis using hind legs from mice (triadin null, junctin null,
triadin/junctin null). Their results showed reduced coup-
ling in triadin-null mice, whereas junctin null mice dem-
onstrated minimal to no changes in functional activity.
Based on these results, the interaction between triadin
and CSQ has a major impact on the SR architecture and
myoplasmic Ca++ [24] as previously noted in group 1.
More specifically, the SR luminal content and volume of
SR cisternae are significantly altered in triadin null and
triadin/junctin null mice. CSQ is also less defined. The
findings from Boncompagni et al. (2012) further support
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triadin as an important factor in skeletal muscle function
as suggested in group 1.
Group 3 Pathomechanisms:
The triadin binding-domain in RyR1 is located within
the hotspot 3 region of which gives rise to CCD and
CCD/MH mutations [78]. Several RYR1 mutations,
resulting in central core disease, lead to amino acid
changes in the SR luminal side of RyR1 that disrupt
RyR1-triadin interaction as well as influence voltage-
gated Ca++ release [11, 67]. I4898T is a very common
RyR1 mutation within this SR luminal region that results
in severe CCD and is proposed to possibly disrupt the
interaction between RyR1 and triadin [95].
Group 4
Group 4, represented in Fig. 1d, responds to changes in
adenosine 3’, 5’ cyclic monophosphate (cAMP), which is
elevated due to acetylcholine (ACh) release. Group 1
responds to an action potential resulting from ACh
release, whereas group 4 responds to elevated cAMP
levels resulting from ACh release. Therefore, these
groups may be activated simultaneously. Group 4 in-
cludes FKBP12, protein kinase A (PKA), phosphodiester-
ase 4D3 (PDE4D3), and protein phosphatase 1 (PP1).
RyR1 undergoes phosphorylation and dephosphorylation
[56] within the group.
cAMP levels are increased in response to acetylcholine
release. As a result, PKA is activated and is anchored to
RyR1 by way of A-kinase anchoring proteins of the skel-
etal muscle (mAKAP). PKA then phosphorylates RyR1
(S2483) preventing the binding of Mg2+ to RyR1, result-
ing in RyR1 open probability. PKA not only phosphory-
lates RyR1, but also phosphorylates the targeting subunit
Gm, which results in the dissociation of PP1 from Gm
and the SR. PP1 dissociation from Gm prevents PP1
from dephosphorylating RyR1. The above pathway re-
sults in RyR1 open probability. However, when cAMP
levels are lowered by PDE4D3, PP1 is not dissociated
from the Gm subunit nor is the Gm subunit separated
from RyR1. PP1 is then able to dephosphorylate RyR1
resulting in FKBP12 binding, thus a RyR1 closed state.
To better understand this portion of the pathway, the
involved proteins of this group are further discussed.
Group 4 has several regulatory components and ap-
pears to be the only group that not only affects voltage-
activated RyR1, but also adjacent non voltage-activated
RyR1. Because group 4 affects both voltage-activated
and non voltage-activated RyR1, this raises the question
of whether mutations in RyR1 affecting this group influ-
ence clinical severity. Several of the aforementioned
studies focused on a single component of the group,
therefore, studies are needed that demonstrate pathome-
chanisms related to all components making up this
group and their associated phenotype. For example,
FKBP12 is responsible for synchronizing gating mecha-
nisms between adjacent RyR1 proteins. Will a mutation
affecting FKBP12 binding affinity to RyR1 and its ability
to synchronize adjacent RyR1 influence severity? Add-
itionally, as mentioned above, PKA phosphorylation and
S-nitrosylation both dissociate FKBP12 from RyR1.
What happens in skeletal muscle if the phosphorylation
site on RyR1 is changed due to a mutation or hyperni-
trosylation? Lastly, in group 1, rycals were mentioned as
a drug that enhances the binding affinity of FKBP12 to
RyR1. Could this be a potential treatment that resolves
any issue resulting from RyR1 mutations in this group?
Further research is needed regarding group 4 and its
related pathomechanisms.
FKBP12
FKBP12 is not only a component of group 1, but also a
component of group 4. In group 4, FKBP12 is an im-
portant regulatory protein. When bound to RyR1, it sta-
bilizes the RyR1 closed state and synchronizes the gating
between neighboring RyRs [39, 43, 147]. Neighboring
RyR1 channels are very close to each other and are mod-
ulated by extracellular ligands, including Ca++, Mg2+,
and ATP. Non-voltage activated neighboring RyR1 chan-
nels are activated via RyR1-RyR1 physical interaction,
and are stabilized by luminal Ca++ and cytosolic ATP/
Mg2+ [109].
FKBP12 is suggested to coordinate this multiprotein
group formation [114] such that bound FKBP12 does
not promote RyR1 activity. However, FKBP12 dissociates
from RyR1 due to PKA phosphorylation at RyR1 sites
S2843 in humans [19, 114] and S2844 in mice [19, 114],
yet becomes bound again due to PP1 activity. PKA and
PP1 functions are discussed below.
Similar to PKA phosphorylation, S-nitrosylation
(group 5) of RyR1 also reduces the binding affinity of
FKBP12 to RyR1; specifically, S-nitrosylation of cysteine
residues at positions 3635 and 2327 [7, 8, 19, 136]. Un-
like PKA, S-nitrosylation does not respond to cAMP as
discussed later under group 5.
PKA
PKA is a holoenzyme with a tetrameric group consisting
of two catalytic (C) subunits and a regulatory subunit
dimer. Adrenaline, a hormone that acts on the skeletal
muscle in response to neural ACh release [91], elevates
cAMP levels resulting in PKA activation, which in turn
induces Gm phosphorylation [149].
cAMP is required for PKA phosphorylation of the
RyR1 channel, otherwise referred to as cAMP-induced
PKA phosphorylation [114]. When cAMP levels are low,
the C subunit binds to the regulatory subunit making
PKA inactive. On the other hand, in the presence of
high levels of cAMP, cAMP binds to the regulatory C
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subunit. In turn, the affinity of the regulatory subunit for
the C subunit is reduced thus freeing the C subunits and
activating PKA [34]. mAKAPs co-localize with RyR1 and
function to anchor PKA to RyR1 in the presence of
elevated cAMP levels [121]. In response, PKA phosphory-
lates serine residue, S2843 [19, 114], on RyR1 subunits in
the sarcoplasm leading to a skeletal muscle contraction
and greater muscle force generation [5]. PKA-dependent
phosphorylation prevents the binding of Mg2+ to the
RyR1 channel thereby increasing RyR1 open probabil-
ity [121].
Additionally, glutathionylation regulates PKA activity,
which regulates RyR1 activity in the presence of cAMP.
PKA cannot be glutathionylated in the absence of cAMP
and is therefore protected from oxidation. In the presence
of cAMP, PKA becomes active. Once active, glutathionyla-
tion makes PKA more susceptible to dephosphorylation,
and thus its’ inhibition. “PKA deglutathionylation leads to
PKA reactivation” [106].
PDE4D3
Like PKA, PDE4D3 is targeted to RyR1 by way of
mAKAP, which is an anchoring protein [19]. PDE4D3 is
specific for cAMP [28]. Phosphodiesterases regulate
cAMP levels by binding and degrading cAMP. PDE4D3,
specifically, functions to control cAMP concentration by
degradation when co-localized with RyR1 [19].
PP1
PP1 dephosphorylates RyR1 [114] resulting in the bind-
ing of FKBP12 to RyR1. PP1 is a serine/threonine kinase
with a catalytic subunit and several targeting subunits.
Specifically, the Gm targeting subunit of PP1 binds and
directs PP1 to glycogen particles and the SR. PP1 binds
to the Gm N-terminus and the SR to its C-terminus.
However, phosphorylation of Gm at Ser67, by PKA, dis-
sociates PP1 from the Gm binding domain subsequently
releasing Gm from both glycogen and the SR [149].
Group 5
Group 5, shown in Fig. 1e, responds to changes in
muscle O2 and glutathione ratio (GSH/GSSG). This
group encompasses protein post-translational modifi-
cations including S-nitrosylation, S-oxidation, S-
glutathionylation, and S-palmitoylation [56] and the
molecules nitric oxide (NO), S-nitrosoglutathione
(GSNO), reduced glutathione (GSH), oxidized gluta-
thione (GSSG), hydrogen peroxide (H2O2).
Within this group, RyR1 serves as a redox sensor
where certain cysteine residues undergo redox reactions
by way of post-translational modifications [7]. RyR1, as a
redox sensor, is enhanced by the aforementioned mole-
cules [9]. Each of these post-translational modifications
occur based on O2 levels, which change depending on
oxygen demand of the active muscle [139].
Post-translational modifications serve as on/off switches
of protein function [96]. S-nitrosylation, S-oxidation (di-
sulfide oxidation), and S-glutathionylation each activate
RyR1 by way of different mechanisms [9]. However, to-
gether, they regulate RyR1 channel activity over a range of
skeletal muscle oxygen tension (pO2) [141].
S-nitrosylation
Physiological pO2 levels (~4–20 mm Hg, 0.5-2.5 %) con-
trol the redox state of thiols in the RyR1 subunits main-
taining the ready state of RyR1. NO, at physiological tissue
pO2 (~10 mm Hg), activates RyR1 by S-nitrosylation of
RyR1 cysteine residues. Both reactive oxygen and nitrogen
species modify RyR1 thiols altering RyR1 channel function
[56, 57]. Oxidation and nitrosylation enhance Ca++ release
from the SR via the RyR1 channel [141].
In skeletal muscle, NO is derived from neuronal NO
synthase (nNOS) and functions to S-nitrosylate proteins
forming S-nitrosothiols [139]. S-nitrosothiols are com-
pounds that S-nitrosate a specific protein cys thiol [25].
S-nitrosoglutathione (GSNO), formed by NO and GSH
interaction, is an example of a nitrosothiol [25]. GSNO,
under atmospheric pO2, GSNO can nitrosylate and glu-
tathionylate RyR1 cysteine residues [9]. Specifically, in
vitro GSNO treatment resulted in nitrosylation of RyR1 aa
residues 1–1509 while decreasing S-nitrosylation at
residues 3120–4475 and 3631–4475. Glutathionylation
occurred at the same residues, further including aa 1396–
2401. Although GSNO is able to both nitrosylate and glu-
tathionylate RyR1, glutathionylation seems to be preferred
[9]. GSNO is the S-nitrosated derivative of glutathione
and is considered to be a pertinent mediator of NO. It is
the intermediate in the formation and degradation of S-
nitrosothiols, and for this reason, it is considered to be po-
tentially therapeutic [25]. GSNO not only activates RyR1
by nitrosylation, but also oxidation (C. Hidalgo 2005).
It is important to note that NO only nitrosylates RyR1
cysteine residues in the presence of CaM and at low
muscle pO2 levels [136, 139]. Specifically, in the skeletal
muscle, 6–8 RyR1 thiols are S-nitrosylated [36, 135].
Cys3635 is one of the 6–8 residues identified that is
nitrosylated at low pO2, but not at high pO2 [141]. Con-
sequently, RyR1 changes conformation to the open state
promoting Ca++ release and muscle force production
[135]. Interestingly, Cys3635 is one cysteine residue that is
unaffected by GSNO for Cys3635 does not discriminate
between O2 levels [75].
Eu et al. (2000) determined that the effect of NO
on RyR activity is dependent on the RyR1 redox state
as well as CaM. Brookes et al. (2004) believe mito-
chondria may serve as a “redox signaling box” by
converting the NO signal into an ROS signal [26, 27].
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This phenomenon only occurs at physiological levels
of NO. In skeletal muscle, NO is produced by nitric
oxide synthases (NOS) in the sarcolemma and muscu-
lar endplate [60] to maintain skeletal muscle response
to increased exercise. It is important to note that
NOS activity inhibits mitochondrial respiration [136].
More specifically, NO in the presence of high [Ca++]
inhibits mitochondrial respiration [27, 133]. However,
pathological levels of NO disrupt this process, affect-
ing mitochondrial function, and, in turn, ATP synthe-
sis and cell function [27, 133].
It has been shown that NO in skeletal muscle is pro-
duced at rest and in greater concentrations with increased
exercise. In addition to the increase in NO, there is also
an increase in reactive oxygen and nitrogen species due to
increased muscle contractile activity. In response to exer-
cise, NOS binds CaM, which enhances NOS activity. CaM
serves as a molecular switch activating the transfer of
electrons that results in NO production [138]. Al-
though CaM plays such a major role in S-nitrosylation,
RyR1-bound Ca++-CaM is left unaffected during the
process [56, 75]. However, Ca++-CaM bound RyR1 at
site Cys3635 (to date, it is the only site known to date)
is affected by S-nitrosylation, reversing its inhibitory
effect and resulting in RyR1 activation [75, 141].
In summary, NO seems to regulate oxidative and
glycolytic activity in skeletal muscle, which is further
discussed in the “oxidative stress” section below. NO
functions to activate RyR1 in the presence of CaM and
low O2 levels. It also functions to inhibit mitochondrial
respiration in the presence of high [Ca++]. On the other
hand, at physiological NO, mitochondria convert the
NO signal into a redox signal yielding reactive nitrogen
and oxygen species. The dominant form of RyR1 myop-
athies manifests clinically due to a leaky RyR1 channel,
which results in excessive skeletal muscle Ca++. Future
research in RyR1 myopathies should not only observe
Ca++ regulation with different RyR1 mutations but also
NOS activity and localization, NO levels, CaM levels
and CaM-bound NOS together. Excessive Ca++, theoret-
ically, would deplete NO, and in turn reduce the
frequency of inhibition of mitochondrial respiration.
Consequently, this could result in excessive production
of RNS and ROS via mitochondrial respiration. If this
is the case, treatment targeting NO signaling may be
beneficial in this patient population.
S-oxidation
S-oxidation is coupled to S-nitrosylation. As muscle O2
levels change, there is a transition from nitrosylation to
oxidation and visa versa. “O2 based signaling is mediated
by reversible RyR1 channel oxidation/reduction coupled
to H2O2 production by SR-resident NADPH oxidase 4
(Nox4) that results in channel activation/deactivation
[140, 141].” Nox4 is considered an O2 sensor in skeletal
muscle. (Sun et al. 2011) Reactive oxygen species (ROS,
superoxide anions and H2O2) are oxidizing molecules
produced by Nox4 [76]. They are generated in proportion
to pO2 in the SR [141].
More specifically, S-oxidation of RyR1 is determined
by muscle pO2 where there is an O2-dependent produc-
tion of H2O2 by Nox4, and so oxidation primarily occurs
at high O2 concentrations [141]. H2O2 are reactive oxy-
gen species that oxidize the RyR1 cys-thiols. Like NO,
ROS activate the RyR1 channel; releasing Ca++ from
the SR.
Oxidants activate RyR1 by producing inter-subunit di-
sulfide linkages [72, 110] whereas CaM-bound RyR1
(ApoCaM and Ca++-CaM) prevents the formation of the
intersubunit disulfide linkages. Conversely, CaM inter-
action with RyR1 is inhibited by oxidation [110].
Hamilton [72] cys3635 has been identified as an inter-
subunit contact site and is located within the CaM bind-
ing region [72]. Moore et al. (1999) identified one CaM
binding site per RyR1 subunit at high or low Ca++ levels.
Interestingly, a mutation at Cys3635 does not interfere
with RyR1 activation by the oxidizing molecule H2O2, as
it is not required for RyR1 to serve as a redox sensor [9].
Essentially, CaM protects RyR1 from oxidation. How-
ever, high concentrations of oxidants (oxidative stress)
may result in the loss of RyR1 bound CaM during which
a person may experience fatigue [110].
Cysteine residues that are coupled to muscle oxygen
tension are located in the cytoplasmic domain of RyR1
and regulate RyR1 interaction with DHPR and FKBP12.
Other cysteine residues are located in hotspot regions
that correspond to different diseased states including MH
and CCD. The residues within the hotspot regions
undergo oxidation, but not glutathionylation. Yet, glu-
tathionylation is a reversible oxidative modification [141].
S-glutathionylation
During physical exercise, endogenous glutathione is
modulated with high oxygen consumption and ROS gen-
eration [111]. Although not well understood, the gluta-
thione ratio dictates cellular redox potential [42, 94].
Physiologically, the sarcoplasm is a reducing environ-
ment in which the protein redox state is dependent on
the GSH/GSSG ratio, and a high GSH/GSSG ratio in the
cytosol creates a redox buffer [42]. A GSH/GSSG ratio
above 100 promotes s-glutathionylation, as does the oxida-
tion of small amounts of GSH [42, 94]. S-glutathionylation
of RyR1 functions to decrease RyR1 sensitivity to Mg2+-
inhibition maintaining RyR1 open probability [7, 8].
To date, researchers have identified the superoxide
anion, H2O2, as a primary oxidizing molecule for RyR1 glu-
tathionylation even though oxidized glutathione (GSSG)
and O2 have also been shown to enhance RyR1 channel
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activity. H2O2, in the presence of reduced glutathione
(GSH), reacts with redox sensitive RyR1 for glutathionyla-
tion of RyR1 as well as enhances the process [7, 75].
Specifically, redox-sensitive proteins, like RyR1, have
cysteine residues that exist as thiolate anions at neutral
pH, unlike proteins that are not redox-sensitive. Proteins
that are not redox sensitive have cysteine residues that
remain protonated. The difference in charge between
cysteine residues that are thiolate anions and cysteine
residues that are protonated, within a redox-sensitive
protein, make the thiolate anions “active cysteines” that
are vulnerable to oxidation. H2O2 oxidizes the protein
thiols creating an unstable protein sulfenic acid that
serves as an intermediate. The sulfenic acid then undergoes
glutathionylation during which they become thiolated
forming a disulfide bond with GSH [42, 106].
In the presence of oxidative stress, proteins are targeted
for s-glutathionylation. GSH then becomes depleted and
there is an increase in the oxidized derivatives (GS-,
GSNO, and GSSG) resulting in a decreased GSH/GSSG
ratio (Mieyal et al. 2008). It is important to note that both
GSNO and GSSG, in addition to GSH, are responsible for
protein glutathionylation. Consequently, under stressful
conditions, these factors may be responsible for the devel-
opment of pathological states through the stimulation of
uncontrolled calcium-induced calcium release [8]. Upon
restoration of the GSH/GSSG ratio, S-glutathionylation is
reversed [42, 49]. Durham et al. (2008) inhibited NOS in
mutant mice, and in doing so, restored the GSH/GSSG
ratio. T-tubule NOS has been shown to promote RyR1
glutathionylation [106]. Under physiological conditions,
NO levels derived from nNOS are lower than the GSH/
GSSG ratio; however, when nNOS-related NO production
increases, the enzymes responsible for glutathione synthe-
sis are inhibited. The Durham results suggest that nitrosa-
tive stress mediates oxidative stress and that GSH/GSSG
ratio is decreased in Y522S mouse models [50, 137].
N-acetylcysteine is a precursor of glutathione and
successfully restored GSH/GSSG ratio in this model.
Hind limb muscle force in the mouse also improved
with NAC [50].
S-palmitoylation
Palmitoylation is a reversible process where the 16-
carbon saturated fatty acid palmitate forms a thioester
link to cysteine thiols creating an acyl chain [23]. Re-
moving palmitate from RyR1 diminishes RyR1 Ca++ re-
lease. S-palmitoylation includes the modification of at
least 18 RyR1 cys residues. These residues have been
identified in protein interaction regions for DHPR, CaM,
and FKBP12. They are also located in RyR1 hot spot
regions that correspond to malignant hyperthermia and
central core disease. Eight of the 18 residues are cys
residues that are also subject to S-nitrosylation and S-
glutathionylation [33].
Palmitoylation is one of the least studied processes in
the RyR1 pathway, yet may be a potential treatment. Pal-
mitoylation removes palmitate from two binding sites
(CaM and FKBP12), of which may function to close the
RyR1 channel. It would be interesting to study the differ-
ences in palmitate levels in RyR1 myopathic muscle
compared with “normal” tissue.
Group 5 Pathomechanisms:
CCD/MH: Cysteine residues at sites 36, 253, and 315
are located in hot spot 1 of RyR1 whereas Cys residues
between 2326 and 2363 are located in hot spot 2.
Mutations at these sites interfere with regulation of
RyR1 resulting in MH [9].
Hyper-S-nitrosylation of RyR1 results in FKBP12
depletion thus leaky channels in muscular dystrophin
mice. Together, hyper-S-nitrosylation and FKBP12
depletion are suggested to contribute to muscle
weakness in muscular dystrophy [20, 74]. This may
also be the case for muscle weakness observed in
individuals with RyR1 myopathies as discussed above
under CCD and S-nitrosylation.
The Y522S mutation in RyR1, although not located in
the RyR1-DHPR binding site, alters DHPR inactivation
during retrograde signaling where there is an increase
in Ca++ release [6]. This mutation is located in hotspot
1 and results in CCD/MH.
Durham et al. (2008) studied S-nitrosylation in RyR1
mice with a point mutation (Y522S) associated with
MH, and in humans, central core disease. The Y522S
mutation resulted in RyR1 Ca++ leak that led to
increased production of reactive nitrogen species (RNS).
S-nitrosylation, following excessive RNS production,
results in “increased temperature sensitivity for RyR1
activation, producing muscle contractures upon exposure
to elevated temperatures.” Additionally, the mitochondria
are abnormally shaped, there is increased mitochondrial
lipid peroxidation, and decreased muscle force production
[50]. In Y522S knock-in mice, there were elevated ROS,
leaky channels, and damaged enlarged mitochondria
[51]. Following N-acetylcysteine administration, the
mitochondria and muscles were protected against
oxidative damage and reduced force production,
respectively [50].
Similar to Y522S, R163C knock-in mice also presented
with greater sarcoplasmic [Ca++] and ROS, but rather a
different pathomechanism and manifests as MH only.
In myotubes of R163C knock-in mice, the Ca++ decay
rate is slowed such that the RyR1 retrograde signal is
altered thus resulting in delayed DHPR inactivation. It
is important to note that MH due to the R163C
mutant does not result in SR Ca++ depletion or RyR1
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inactivation suggesting no leaky channels [55]. Another
study of the R163C mutant mouse, showed increased
mitochondrial Ca++ and ROS as well as reduced oxidative
phosphorylation and lower mitochondrial protein
expression. Ultimately, the R163C mutation results
in elevated sarcoplasmic resting Ca++ levels [51, 66]
Abnormal oxidation of RyR1 cys thiols may be connected
to dysregulation of S-nitrosylation, of which leads to an
RyR1 Ca++ leak resulting in various muscle pathologies,
including exercise-induced fatigue, CCD, and MH
[9, 140]. RyR1 activation due to oxidation is prevented
by NO, of which nitrosylation is CAM dependent
[1, 113]. Conversely, RyR1 is activated by oxidation
of RyR1 cys thiols at high PO2 concentration and
this oxidation prevents S-nitrosylation of a separate
cys thiol that activates RyR1 at low PO2 [56, 57, 140].
CCD or MH: S-palmitoylation targets cysteine residues
in the hot spot regions that are linked to MH and CCD
and are interaction sites for DHPR, CaM, and FKBP12
[33]. The severity of one’s condition or onset of MH
may be due to post-translational modifications at
CCD/MH mutation sites.
Exercise Intolerance: During exercise, RyR1 is
progressively PKA-hyperphosphorylated, S-nitrosylated,
and depleted of PDE4D3 and FKBP12 ultimately
resulting in “leaky” channels thus decreased exercise
tolerance. S107, a type of Rycal, prevents the depletion
of FKBP12, and in turn improves force generation and
exercise capacity [19]. FKBP12 dissociates from RyR1
due to PKA phosphorylation at RyR1 sites S2843 in
humans [114] and S2844 in mice [19, 114]. However, a
mutation (S2843A and S2844A) at these sites does not
allow for PKA phosphorylation of the RyR1 channel
and thus a decrease in the RyR1 open probability.
S2843D and S2844D mutations, on the other hand,
mimic PKA phosphorylation otherwise referred to
as hyperphosphorylation, thus increasing RyR1 open
probability [19, 114].
Group 6
Group 6 seems to respond to [Ca++]. This group includes
three different ligands including calcium (Ca++), adenosine
triphosphate (ATP), and magnesium (Mg2+), which are
extracellular ligands that regulate RyR1 activity [56]. RyR1
includes two types of sites for ligand binding, activation
and inhibitory sites. The activation sites are referred to as
A-sites, whereas the inhibitory sites are called I-sites [92].
Ca++ and ATP bind to the RyR1 A-sites increasing RyR1
open probability, whereas Ca++ and Mg2+ bind to the I-
sites promoting the RyR1 closed state [88, 92] I-sites are
divalent, nonspecific cation sites to which both Ca++ and
Mg2+ bind. The binding affinity of these cations to the I-
sites are unaffected by ATP unlike the binding of activating
Ca++ to the A-sites [88]. Figure 1f outlines the group 6.
Ca++
Recently, RyR1 has been shown to have an alpha solen-
oid scaffold in the cytosolic region. In the core solenoid
(starting at aa3679) of this region, there are calmodulin
(CaM)-like binding domains referred to as the putative
Ca++ binding domain and suggested to serve as Ca++
sensors. “Six of the eight residues that coordinate Ca++
in CaM are conserved in the putative Ca++-binding do-
main of RyR1. Since the S2 and S3 helices (aa4675-4790)
are located close to putative Ca++ binding domains and
the C-terminal, it is thought that they contribute to trans-
mitting Ca++-mediated RyR1 conformational changes to
the cytosolic formation of the pore [156].
Ca++ has both an activating and inhibitory effect on
RyR1 when bound [88]. Physiologic Ca++ levels yield an
un-stimulatory effect on RyR1 [54]. Upon skeletal
muscle stimulation, Ca++ is released from the SR into
the sarcoplasm triggering several downstream events
[54]. As evidenced by RyR1 truncation experiments, Ca++
activation sites are suggested to be located between
aa4007-5037, within the pore-forming region of the RyR1
cytoplasmic subunits. Ca++ activation sites on ryanodine
receptors are located in the cytoplasmic region of ryano-
dine receptors and are referred to as A-sites. Specifically,
aa4032 is a part of the “A-site gating-mechanism” as evi-
denced by the introduction of the E4032A mutation,
which led to a significant decrease in sarcoplasmic Ca++
activation [88]. Amino acids 1873–1903, 1641–2437, and
615 have been implicated as the inhibitory sites.
ATP
When bound to ATP at one or more of its ATP binding
sites, RyR1 is activated. However, the interaction between
ATP and RyR1 is affected by Ca++, Mg2+, and pharmaco-
logic agents including dantrolene [44]. In the presence of
activating Ca++, the ATP binding affinity decreases,
whereas it increases in the presence of inhibitory Ca++. Al-
though the ATP binding affinity increases in the presence
of inhibitory Ca++, the number of ATP accessible sites de-
creases [44]. The different sites at which ATP binds has
yet to be determined. Popova et al. (2012) identified four
potential ATP binding sites on RyR1 including aa 699–
704, 701–706, 1081–1084, and 1195–1200. These sites are
located next to the RyR1 hotspot regions [108].
Mg2+
In contrast to ATP, Mg2+ inhibits RyR1 activity. Mg2+
binds to both high affinity Ca++ activation sites as well
Mg2+ inhibitory sites [38]. Although Mg2+ binds to the A-
site, it does not activate the RyR1 channel [92]. Instead, it
yields an inhibitory effect by reducing RyR1 sensitivity to
Ca++ [54]. Under normal physiological conditions, Mg2+
remains bound to the RyR1 I-sites inhibiting the activation
effect of both Ca++ and ATP [92].
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Conclusion
In this review, several studies were compiled to outline
the RyR1 pathway and RYR1-RM-related pathomechan-
isms in an effort to highlight potential target sites for
treatment as well as areas that require further explor-
ation. Given the complexity of the pathway, we divided
its interactions and modifications into six regulatory
groups. FKBP12, Triadin, and CaM were the only identified
interacting proteins that function across all six groups. Not
only do they function across groups, but pathogenic muta-
tions located at their RyR1 interaction sites also clinically
present as CCD, MmD, and CNM [3, 65, 78, 104]. Add-
itionally, post-translational modifications in the presence of
mutations related to FKBP12 and CaM binding sites
contribute to CCD/MH [19, 33, 50, 114]. Based on this
information, these interaction sites serve as potential sites
of treatment targets.
Evidently, post-translational modifications also play a
major role in regulating the RyR1 channel. For example,
nitric oxide nitrosylates RyR1 but also affects mitochon-
drial activity [50]. Additionally, nitrosylation in the pres-
ence certain RyR1 mutations, such as Y522S, increases
temperature sensitivity of RyR1 activation to elevated
temperatures. Thus further research related to hyper-
nitrosylation and its role in disease severity is needed. Oxi-
dation is coupled to nitrosylation such that both processes
mediate the other [1, 9, 113, 140]. Phosphorylation affects
FKBP12 in the sarcoplasm, CSQ activity in the SR, and
PP1 activity that influences RyR1 function [19, 114]. Pal-
mitoylation occurs at binding sites for FKBP12, CaM, and
DHPR as well as at sites that are subject to nitrosylation
and glutathionylation [33]. The interplay between different
post-translational modifications may contribute to disease
severity in the presence of pathogenic mutations.
Although much remains to be learned about the RyR1
pathway, the potential for effective treatments exists based
on what is currently known. As mentioned previously, we
are currently performing the first randomized, placebo-
controlled, double-blinded drug trial in patients with
RYR1-RM using N-acetylcysteine to target mitochondrial
oxidative stress [48]. Additionally, pre-clinical studies are
ongoing using rycals, which target FKBP12 binding affinity
[4, 20], one of the three interacting proteins that functions
across groups. Gene replacement therapy has also been
considered for RYR1-RM but proves difficult due to the
large size of the RYR1 gene and the challenge of inserting
the full gene into a delivery vector [115]. On the other
hand, CRISPR/Cas9 technology offers promise by correct-
ing the specific mutation in each patient and is currently
in beginning stages in mouse models of RYR1-RM. As
RyR1 plays a major role in skeletal muscle calcium regula-
tion in general, components of these potential therapies
may apply to RYR1-RM plus other conditions related to
calcium dysregulation in the future.
Acknowledgements
We thank Carmel Nichols and Alan Hoofring for sketching initial drawings
of groups and adding revisions to manuscript. Joan K. Austin, PhD for
contributing critical revisions to manuscript. Gaetano Santulli, MD, PhD for
suggesting further articles to add to strengthen the manuscript. This work
was supported by the National Institutes of Health, National Institute of
Nursing Research, and Division of Intramural Research.
Authors’ contributions
JWW reviewed literature, prepared manuscript, designed and developed
figures of RyR1 groups, and performed revisions to manuscript and amino
acid table. KGM prepared introduction and amino acid table, and performed
revisions to manuscript and figures of RyR1 groups. Both authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 September 2016 Accepted: 2 November 2016
References
1. Aghdasi B, Reid MB, Hamilton SL (1997) Nitric oxide protects the skeletal
muscle Ca2+ release channel from oxidation induced activation. J Biol
Chem 272:25462–25467
2. Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling
JJ (2011) Prevalence of congenital myopathies in a representative pediatric
united states population. Ann Neurol 70:662–665. doi:10.1002/ana.22510
3. Amburgey K, Bailey A, Hwang JH, Tarnopolsky MA, Bonnemann CG, Medne
L, Mathews KD, Collins J, Daube JR, Wellman GP et al (2013) Genotype-
phenotype correlations in recessive RYR1-related myopathies. Orphanet J
Rare Dis 8:117. doi:10.1186/1750-1172-8-117
4. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W,
Shiomi T, Zalk R, Lacampagne A, Marks AR (2011) Ryanodine receptor
oxidation causes intracellular calcium leak and muscle weakness in aging.
Cell Metab 14:196–207. doi:10.1016/j.cmet.2011.05.014
5. Andersson DC, Meli AC, Reiken S, Betzenhauser MJ, Umanskaya A, Shiomi T,
D’Armiento J, Marks AR (2012) Leaky ryanodine receptors in beta-sarcoglycan
deficient mice: a potential common defect in muscular dystrophy. Skelet
Muscle 2:9. doi:10.1186/2044-5040-2-9
6. Andronache Z, Hamilton SL, Dirksen RT, Melzer W (2009) A retrograde signal
from RyR1 alters DHP receptor inactivation and limits window Ca2+ release
in muscle fibers of Y522S RyR1 knock-in mice. Proc Natl Acad Sci U S A 106:
4531–4536. doi:10.1073/pnas.0812661106
7. Aracena P, Tang W, Hamilton SL, Hidalgo C (2005) Effects of S-glutathionylation
and S-nitrosylation on calmodulin binding to triads and FKBP12 binding
to type 1 calcium release channels. Antioxid Redox Signal 7:870–881.
doi:10.1089/ars.2005.7.870
8. Aracena-Parks P, Sanchez G, Donoso P, Hamilton SL, Hidalgo C (2003) S-
glutathionylation decreases Mg2+ inhibition and s-nitrosylation enhances
Ca2+ activation of RyR1 channels. J Biol Chem 278:42927
9. Aracena-Parks P, Goonasekera SA, Gilman CP, Dirksen RT, Hidalgo C,
Hamilton SL (2006) Identification of cysteines involved in S-nitrosylation, S-
glutathionylation, and oxidation to disulfides in ryanodine receptor type 1.
J Biol Chem 281:40354–40368. doi:10.1074/jbc.M600876200
10. Attali R, Aharoni S, Treves S, Rokach O, Becker Cohen M, Fellig Y, Straussberg R,
Dor T, Daana M, Mitrani-Rosenbaum S et al (2013) Variable myopathic
presentation in a single family with novel skeletal RYR1 mutation. PLoS
One 8:e69296. doi:10.1371/journal.pone.0069296
11. Avila G, Lee EH, Perez CF, Allen PD, Dirksen RT (2003) FKBP12 binding to RyR1
modulates excitation-contraction coupling in mouse skeletal myotubes. J Biol
Chem 278:22600–22608. doi:10.1074/jbc.M205866200
12. Bannister ML, Hamada T, Murayama T, Harvey PJ, Casarotto MG, Dulhunty AF,
Ikemoto N (2007) Malignant hyperthermia mutation sites in the Leu2442-
Pro2477 (DP4) region of RyR1 (ryanodine receptor 1) are clustered in
a structurally and functionally definable area. Biochem J 401:333–339.
doi:10.1042/BJ20060902
13. Beard NA, Laver DR, Dulhunty AF (1999) Regulation of skeletal muscle
ryanodine receptors by calsequestrin. Proceedings of the Australian
Physiological and Pharmacological Society, City, p 43P
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 16 of 20
14. Beard NA, Dulhunty AF, Laver DR (2000) The effect of increasing luminal
calcium on skeletal muscle calsequestrin. Proceedings of the Australian
Physiological and Pharmacalogical Society, City, p 43P
15. Beard NA, Sakowska MM, Dulhunty AF, Laver DR (2002) Calsequestrin is an
inhibitor of skeletal muscle ryanodine receptor calcium release channels.
Biophys J 82:310–320. doi:10.1016/S0006-3495(02)75396-4
16. Beard NA, Casarotto MG, Wei L, Varsanyi M, Laver DR, Dulhunty AF (2005)
Regulation of ryanodine receptors by calsequestrin: effect of high luminal Ca2+
and phosphorylation. Biophys J 88:3444–3454. doi:10.1529/biophysj.104.051441
17. Beard NA, Wei L, Cheung SN, Kimura T, Varsanyi M, Dulhunty AF (2008)
Phosphorylation of skeletal muscle calsequestrin enhances its Ca2+ binding
capacity and promotes its association with junctin. Cell Calcium 44:363–373
18. Beard NA, Wei L, Dulhunty AF (2009) Ca(2+) signaling in striated muscle: the
elusive roles of triadin, junctin, and calsequestrin. Eur Biophys J 39:27–36.
doi:10.1007/s00249-009-0449-6
19. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, Landry DW, Nieman D,
Lehnart SE, Samaru M, LaCampagne A et al (2008) Remodeling of ryanodine
receptor complex causes “leaky” channels: a molecular mechanism for
decreased exercise capacity. Proc Natl Acad Sci U S A 105:2198–2202.
doi:10.1073/pnas.0711074105
20. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S,
Lacampagne A, Marks AR (2009) Hypernitrosylated ryanodine receptor calcium
release channels are leaky in dystrophic muscle. Nat Med 15:325–330.
doi:10.1038/nm.1916
21. Bevilacqua JA, Monnier N, Bitoun M, Eymard B, Ferreiro A, Monges S,
Lubieniecki F, Taratuto AL, Laquerriere A, Claeys KG et al (2011) Recessive
RYR1 mutations cause unusual congenital myopathy with prominent
nuclear internalization and large areas of myofibrillar disorganization.
Neuropathol Appl Neurobiol 37:271–284. doi:10.1111/j.1365-2990.2010.01149.x
22. Bharucha-Goebel DX, Santi M, Medne L, Zukosky K, Dastgir J, Shieh PB, Winder
T, Tennekoon G, Finkel RS, Dowling JJ et al (2013) Severe congenital RYR1-
associated myopathy: the expanding clinicopathologic and genetic spectrum.
Neurology 80:1584–1589. doi:10.1212/WNL.0b013e3182900380
23. Blaskovic S, Blanc M, van der Goot FG (2013) What does S-palmitoylation
do to membrane proteins? FEBS J 280:2766–2774. doi:10.1111/febs.12263
24. Boncompagni S, Thomas M, Lopez JR, Allen PD, Yuan Q, Kranias EG,
Franzini-Armstrong C, Perez CF (2012) Triadin/Junctin double null mouse
reveals a differential role for Triadin and Junctin in anchoring CASQ to the
jSR and regulating Ca(2+) homeostasis. PLoS One 7:e39962.
doi:10.1371/journal.pone.0039962
25. Broniowska KA, Diers AR, Hogg N (2013) S-nitrosoglutathione. Biochim
Biophys Acta 1830:3173–3181. doi:10.1016/j.bbagen.2013.02.004
26. Brookes P, Darley-Usmar VM (2002) Hypothesis: the mitochondrial NO(*)
signaling pathway, and the transduction of nitrosative to oxidative cell
signals: an alternative function for cytochrome C oxidase. Free Radic Biol
Med 32:370–374
27. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS (2004) Calcium, ATP,
and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 287:
C817–C833. doi:10.1152/ajpcell.00139.2004
28. Capes EM, Loaiza R, Valdivia HH (2011) Ryanodine receptors. Skelet Muscle
1:18. doi:10.1186/2044-5040-1-18
29. Carsana A (2014) RYR1-Related myopathies and anesthesiological implications.
Int J Clin Anesthesiol 2:1037–1041
30. Caswell AH, Motoike HK, Fan H, Brandt NR (1999) Location of ryanodine
receptor binding site on skeletal muscle triadin. Biochemistry 38:90–97.
doi:10.1021/bi981306+
31. Catterall WA (2000) Structure and regulation of voltage-gated Ca2+ channels.
Annu Rev Cell Dev Biol 16:521–555. doi:10.1146/annurev.cellbio.16.1.521
32. Catterall WA (2011) Voltage-gated calcium channels. Cold Spring Harb
Perspect Biol 3:a003947. doi:10.1101/cshperspect.a003947
33. Chaube R, Hess DT, Wang YJ, Plummer B, Sun QA, Laurita K, Stamler JS (2014)
Regulation of the skeletal muscle ryanodine receptor/Ca2 + −release channel
RyR1 by S-palmitoylation. J Biol Chem 289:8612–8619. doi:10.1074/jbc.M114.
548925
34. Cheng X, Ma Y, Moore M, Hemmings BA, Taylor SS (1998) Phosphorylation
and activation of cAMP-dependent protein kinase by phosphoinositide-
dependent protein kinase. Proc Natl Acad Sci U S A 95:9849–9854
35. Cheng W, Altafaj X, Ronjat M, Coronado R (2005) Interaction between the
dihydropyridine receptor Ca2+ channel beta-subunit and ryanodine receptor
type 1 strengthens excitation-contraction coupling. Proc Natl Acad Sci U S A
102:19225–19230. doi:10.1073/pnas.0504334102
36. Cheong E, Tumbev V, Stoyanovsky D, Salama G (2005) Effects of pO2 on the
activation of skeletal muscle ryanodine receptors by NO: a cautionary note.
Cell Calcium 38:481–488. doi:10.1016/j.ceca.2005.07.001
37. Clarke NF, Waddell LB, Cooper ST, Perry M, Smith RL, Kornberg AJ, Muntoni
F, Lillis S, Straub V, Bushby K et al (2010) Recessive mutations in RYR1 are
a common cause of congenital fiber type disproportion. Hum Mutat 31:
E1544–E1550. doi:10.1002/humu.21278
38. Copello JA, Barg S, Sonnleitner A, Porta M, Diaz-Sylvester P, Fill M, Schindler H,
Fleischer S (2002) Differential activation by Ca2+, ATP and caffeine of cardiac
and skeletal muscle ryanodine receptors after block by Mg2+. J Membr Biol
187:51–64. doi:10.1007/s00232-001-0150-x
39. Corona BT, Rouviere C, Hamilton SL (1985) Ingalls CP (2008) FKBP12 deficiency
reduces strength deficits after eccentric contraction-induced muscle injury.
J Appl Physiol 105:527–537. doi:10.1152/japplphysiol.01145.2007
40. Cuperman T, Fernandes SA, Lourenco NC, Yamamoto LU, Silva HC,
Pavanello RC, Yamamoto GL, Zatz M, Oliveira AS, Vainzof M (2014) Silent
polymorphisms in the RYR1 gene do not modify the phenotype of the p.
4898 I > T pathogenic mutation in central core disease: a case report. BMC
Res Notes 7:487. doi:10.1186/1756-0500-7-487
41. D’Arcy CE, Bjorksten A, Yiu EM, Bankier A, Gillies R, McLean CA, Shield LK,
Ryan MM (2008) King-denborough syndrome caused by a novel mutation
in the ryanodine receptor gene. Neurology 71:776–777. doi:10.1212/01.wnl.
0000324929.33780.2f
42. Dalle-Donne I, Rossi R, Giustarini D, Colombo R, Milzani A (2007) S-
glutathionylation in protein redox regulation. Free Radic Biol Med 43:
883–898. doi:10.1016/j.freeradbiomed.2007.06.014
43. Danila CI, Hamilton SL (2004) Phosphorylation of ryanodine receptors. Biol
Res 37:521–525
44. Dias JM, Vogel PD (2009) Effects of small molecule modulators on ATP
binding to skeletal ryanodine receptor. Protein J 28:240–246. doi:10.1007/
s10930-009-9189-9
45. Disease NOfR (2007) Central core disease https://rarediseases.org/rare-
diseases/central-core-disease/. Accessed 18 Oct 2016.
46. Donkervoort S, Bonnemann CG, Loeys B, Jungbluth H, Voermans NC (2015)
The neuromuscular differential diagnosis of joint hypermobility. Am J Med
Genet C Semin Med Genet 169C:23–42. doi:10.1002/ajmg.c.31433
47. Dowling JJ, Lillis S, Amburgey K, Zhou H, Al-Sarraj S, Buk SJ, Wraige E, Chow
G, Abbs S, Leber S et al (2011) King-Denborough syndrome with and
without mutations in the skeletal muscle ryanodine receptor (RYR1) gene.
Neuromuscul Disord 21:420–427. doi:10.1016/j.nmd.2011.03.006
48. Dowling JJ, Arbogast S, Hur J, Nelson DD, McEvoy A, Waugh T, Marty I,
Lunardi J, Brooks SV, Kuwada JY et al (2012) Oxidative stress and successful
antioxidant treatment in models of RYR1-related myopathy. Brain 135:1115–1127.
doi:10.1093/brain/aws036
49. Dulce RA, Schulman IH, Hare JM (2011) S-glutathionylation: a redox-sensitive
switch participating in nitroso-redox balance. Circ Res 108:531–533. doi:10.
1161/RES.0b013e3182147d74
50. Durham WJ, Aracena-Parks P, Long C, Rossi AE, Goonasekera SA, Boncompagni
S, Galvan DL, Gilman CP, Baker MR, Shirokova N et al (2008) RyR1 S-nitrosylation
underlies environmental heat stroke and sudden death in Y522S RyR1 knockin
mice. Cell 133:53–65. doi:10.1016/j.cell.2008.02.042
51. Eisner V, Lenaers G, Hajnoczky G (2014) Mitochondrial fusion is frequent in
skeletal muscle and supports excitation-contraction coupling. J Cell Biol 205:
179–195. doi:10.1083/jcb.201312066
52. Eltit JM, Feng W, Lopez JR, Padilla IT, Pessah IN, Molinski TF, Fruen BR, Allen
PD, Perez CF (2010) Ablation of skeletal muscle triadin impairs FKBP12/RyR1
channel interactions essential for maintaining resting cytoplasmic Ca2+.
J Biol Chem 285:38453–38462. doi:10.1074/jbc.M110.164525
53. Eltit JM, Li H, Ward CW, Molinski T, Pessah IN, Allen PD, Lopez JR (2011)
Orthograde dihydropyridine receptor signal regulates ryanodine receptor passive
leak. Proc Natl Acad Sci U S A 108:7046–7051. doi:10.1073/pnas.1018380108
54. Endo M (2009) Calcium-induced calcium release in skeletal muscle. Physiol
Rev 89:1153–1176. doi:10.1152/physrev.00040.2008
55. Esteve E, Eltit JM, Bannister RA, Liu K, Pessah IN, Beam KG, Allen PD, Lopez
JR (2010) A malignant hyperthermia-inducing mutation in RYR1 (R163C):
alterations in Ca2+ entry, release, and retrograde signaling to the DHPR.
J Gen Physiol 135:619–628. doi:10.1085/jgp.200910328
56. Eu JP, Sun J, Xu L, Stamler JS, Meissner G (2000) The skeletal muscle calcium
release channel: coupled O2 sensor and NO signaling functions. Cell 102:499–509
57. Eu JP, Hare JM, Hess DT, Skaf M, Sun J, Cardenas-Navina I, Sun QA, Dewhirst
M, Meissner G, Stamler JS (2003) Concerted regulation of skeletal muscle
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 17 of 20
contractility by oxygen tension and endogenous nitric oxide. Proc Natl
Acad Sci U S A 100:15229–15234. doi:10.1073/pnas.2433468100
58. Fan H, Brandt NR, Peng M, Schwartz A, Caswell AH (1995) Binding sites of
monoclonal antibodies and dihydropyridine receptor alpha 1 subunit
cytoplasmic II-III loop on skeletal muscle triadin fusion peptides. Biochemistry
34:14893–14901
59. Ferreiro A, Monnier N, Romero NB, Leroy JP, Bonnemann C, Haenggeli CA,
Straub V, Voss WD, Nivoche Y, Jungbluth H et al (2002) A recessive form of
central core disease, transiently presenting as multi-minicore disease, is
associated with a homozygous mutation in the ryanodine receptor type 1
gene. Ann Neurol 51:750–759. doi:10.1002/ana.10231
60. Fujii Y, Guo Y, Hussain SN (1998) Regulation of nitric oxide production in
response to skeletal muscle activation. J Appl Physiol (1985) 85:2330–2336
61. Gaburjakova M, Gaburjakova J, Reiken S, Huang F, Marx SO, Rosemblit N,
Marks AR (2001) FKBP12 binding modulates ryanodine receptor channel
gating. J Biol Chem 276:16931–16935. doi:10.1074/jbc.M100856200
62. Galfre E, Venturi E, Pitt SJ, Bellamy S, Sessions RB, Sitsapesan R (2013) Investigating
the Relationship between FKBP Structure and the Ability to Activate RyR
Channels. Biophys J 104:443a, http://dx.doi.org/10.1016/j.bpj.2012.11.2459
63. Gangopadhyay JP, Ikemoto N (2008) Interaction of the Lys(3614)-Asn(3643)
calmodulin-binding domain with the Cys(4114)-Asn(4142) region of the type 1
ryanodine receptor is involved in the mechanism of Ca2+/agonist-induced
channel activation. Biochem J 411:415–423. doi:10.1042/BJ20071375
64. Gehlert S, Bloch W, Suhr F (2015) Ca2 + −dependent regulations and
signaling in skeletal muscle: from electro-mechanical coupling to
adaptation. Int J Mol Sci 16:1066–1095. doi:10.3390/ijms16011066
65. Girgenrath T, Mahalingam M, Svensson B, Nitu FR, Cornea RL, Fessenden JD
(2013) N-terminal and central segments of the type 1 ryanodine receptor
mediate its interaction with FK506-binding proteins. J Biol Chem 288:
16073–16084. doi:10.1074/jbc.M113.463299
66. Giulivi C, Ross-Inta C, Omanska-Klusek A, Napoli E, Sakaguchi D, Barrientos G,
Allen PD, Pessah IN (2011) Basal bioenergetic abnormalities in skeletal
muscle from ryanodine receptor malignant hyperthermia-susceptible R163C
knock-in mice. J Biol Chem 286:99–113. doi:10.1074/jbc.M110.153247
67. Goonasekera SA, Beard NA, Groom L, Kimura T, Lyfenko AD, Rosenfeld A,
Marty I, Dulhunty AF, Dirksen RT (2007) Triadin binding to the C-terminal
luminal loop of the ryanodine receptor is important for skeletal muscle
excitation contraction coupling. J Gen Physiol 130:365–378. doi:10.1085/jgp.
200709790
68. Groh S, Marty I, Ottolia M, Prestipino G, Chapel A, Villaz M, Ronjat M (1999)
Functional interaction of the cytoplasmic domain of triadin with the skeletal
ryanodine receptor. J Biol Chem 274:12278–12283
69. Guo W, Campbell KP (1995) Association of triadin with the ryanodine receptor
and calsequestrin in the lumen of the sarcoplasmic reticulum. J Biol Chem 270:
9027–9030
70. Guo W, Jorgensen AO, Campbell KP (1996) Triadin, a linker for calsequestrin
and the ryanodine receptor. Soc Gen Physiol Ser 51:19–28
71. Hadad N, Zable AC, Abramson JJ, Shoshan-Barmatz V (1994) Ca2+ binding
sites of the ryanodine receptor/Ca2+ release channel of sarcoplasmic reticulum.
Low affinity binding site(s) as probed by terbium fluorescence. J Biol Chem 269:
24864–24869
72. Hamilton SL, Reid MB (2000) RyR1 modulation by oxidation and calmodulin.
Antioxid Redox Signal 2:41–45
73. Hamilton SL, Serysheva I, Strasburg GM (2000) Calmodulin and Excitation-
Contraction Coupling. News Physiol Sci 15:281–284
74. Hess DT, Stamler JS (2012) Regulation by S-nitrosylation of protein post-
translational modification. J Biol Chem 287:4411–4418. doi:10.1074/jbc.R111.285742
75. Hidalgo C (2005) Cross talk between Ca2+ and redox signalling cascades
in muscle and neurons through the combined activation of ryanodine
receptors/Ca2+ release channels. Philos Trans R Soc Lond B Biol Sci 360:
2237–2246. doi:10.1098/rstb.2005.1759
76. Hidalgo C, Sanchez G, Barrientos G, Aracena-Parks P (2006) A transverse
tubule NADPH oxidase activity stimulates calcium release from isolated
triads via ryanodine receptor type 1 S -glutathionylation. J Biol Chem 281:
26473–26482. doi:10.1074/jbc.M600451200
77. Huang X, Fruen B, Farrington DT, Wagenknecht T, Liu Z (2012) Calmodulin-
binding locations on the skeletal and cardiac ryanodine receptors. J Biol
Chem 287:30328–30335. doi:10.1074/jbc.M112.383109
78. Hwang JH, Zorzato F, Clarke NF, Treves S (2012) Mapping domains and
mutations on the skeletal muscle ryanodine receptor channel. Trends Mol
Med 18:644–657. doi:10.1016/j.molmed.2012.09.006
79. Ikemoto N, Ronjat M, Meszaros LG, Koshita M (1989) Postulated role of
calsequestrin in the regulation of calcium release from sarcoplasmic
reticulum. Biochemistry 28:6764–6771
80. Illingworth MA, Main M, Pitt M, Feng L, Sewry CA, Gunny R, Vorstman
E, Beeson D, Manzur A, Muntoni F et al (2014) RYR1-related congenital
myopathy with fatigable weakness, responding to pyridostigimine.
Neuromuscul Disord 24:707–712. doi:10.1016/j.nmd.2014.05.003
81. Jungbluth H (2007) Multi-minicore Disease. Orphanet J Rare Dis 2:31.
doi:10.1186/1750-1172-2-31
82. Jungbluth H, Gautel M (2014) Pathogenic mechanisms in centronuclear
myopathies. Front Aging Neurosci 6:339. doi:10.3389/fnagi.2014.00339
83. Jungbluth H, Sewry CA, Muntoni F (2011) Core myopathies. Semin Pediatr
Neurol 18:239–249. doi:10.1016/j.spen.2011.10.005
84. Kawasaki T, Kasai M (1994) Regulation of calcium channel in sarcoplasmic
reticulum by calsequestrin. Biochem Biophys Res Commun 199:1120–1127.
doi:10.1006/bbrc.1994.1347
85. Klein A, Lillis S, Munteanu I, Scoto M, Zhou H, Quinlivan R, Straub V, Manzur
AY, Roper H, Jeannet PY et al (2012) Clinical and genetic findings in a large
cohort of patients with ryanodine receptor 1 gene-associated myopathies.
Hum Mutat 33:981–988. doi:10.1002/humu.22056
86. Lamb GD, Stephenson DG (1991) Effect of Mg2+ on the control of Ca2+
release in skeletal muscle fibres of the toad. J Physiol 434:507–528
87. Lamb GD, Cellini MA, Stephenson DG (2001) Different Ca2+ releasing action
of caffeine and depolarisation in skeletal muscle fibres of the rat. J Physiol
531:715–728
88. Laver DR (2007) Ca2+ stores regulate ryanodine receptor Ca2+ release
channels via luminal and cytosolic Ca2+ sites. Clin Exp Pharmacol Physiol
34:889–896. doi:10.1111/j.1440-1681.2007.04708.x
89. Lee JM, Rho SH, Shin DW, Cho C, Park WJ, Eom SH, Ma J, Kim DH (2004)
Negatively charged amino acids within the intraluminal loop of ryanodine
receptor are involved in the interaction with triadin. J Biol Chem 279:
6994–7000. doi:10.1074/jbc.M312446200
90. Lueck J, Goonasekera SA, Dirksen R (2004) Ryanodinopathies: muscle disorders
linked to mutations in ryanodine receptors. Basic Appl Myol 14:345–358
91. Lynch GS, Ryall JG (2008) Role of beta-adrenoceptor signaling in skeletal
muscle: implications for muscle wasting and disease. Physiol Rev 88:729–767.
doi:10.1152/physrev.00028.2007
92. MacIntosh BR, Holash RJ, Renaud JM (2012) Skeletal muscle fatigue–regulation
of excitation-contraction coupling to avoid metabolic catastrophe. J Cell Sci
125:2105–2114. doi:10.1242/jcs.093674
93. Melzer W (2013) Skeletal muscle fibers: Inactivated or depleted after long
depolarizations? J Gen Physiol 141:517–520. doi:10.1085/jgp.201310997
94. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD (2008)
Molecular mechanisms and clinical implications of reversible protein
S-glutathionylation. Antioxid Redox Signal 10:1941–1988. doi:10.1089/ars.
2008.2089
95. Monnier N, Romero NB, Lerale J, Nivoche Y, Qi D, MacLennan DH, Fardeau
M, Lunardi J (2000) An autosomal dominant congenital myopathy with
cores and rods is associated with a neomutation in the RYR1 gene
encoding the skeletal muscle ryanodine receptor. Hum Mol Genet
9:2599–2608
96. Munday AD, Lopez JA (2007) Posttranslational protein palmitoylation:
promoting platelet purpose. Arterioscler Thromb Vasc Biol 27:1496–1499.
doi:10.1161/ATVBAHA.106.136226
97. Nakai J, Dirksen RT, Nguyen HT, Pessah IN, Beam KG, Allen PD (1996)
Enhanced dihydropyridine receptor channel activity in the presence of
ryanodine receptor. Nature 380:72–75. doi:10.1038/380072a0
98. Nakai J, Sekiguchi N, Rando TA, Allen PD, Beam KG (1998) Two regions of
the ryanodine receptor involved in coupling with L-type Ca2+ channels.
J Biol Chem 273:13403–13406
99. O’Connell KM, Yamaguchi N, Meissner G, Dirksen RT (2002) Calmodulin
binding to the 3614–3643 region of RyR1 is not essential for excitation-
contraction coupling in skeletal myotubes. J Gen Physiol 120:337–347
100. O’Reilly FM, Robert M, Jona I, Szegedi C, Albrieux M, Geib S, De Waard M,
Villaz M, Ronjat M (2002) FKBP12 modulation of the binding of the skeletal
ryanodine receptor onto the II-III loop of the dihydropyridine receptor.
Biophys J 82:145–155. doi:10.1016/S0006-3495(02)75381-2
101. Oddoux S, Brocard J, Schweitzer A, Szentesi P, Giannesini B, Brocard J,
Faure J, Pernet-Gallay K, Bendahan D, Lunardi J et al (2009) Triadin
deletion induces impaired skeletal muscle function. J Biol Chem 284:
34918–34929. doi:10.1074/jbc.M109.022442
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 18 of 20
102. Ohkura M, Ide T, Furukawa K, Kawasaki T, Kasai M, Ohizumi Y (1995)
Calsequestrin is essential for the Ca2+ release induced by myotoxin alpha in
skeletal muscle sarcoplasmic reticulum. Can J Physiol Pharmacol 73:1181–1185
103. Ohkura M, Furukawa K, Fujimori H, Kuruma A, Kawano S, Hiraoka M, Kuniyasu
A, Nakayama H, Ohizumi Y (1998) Dual regulation of the skeletal muscle
ryanodine receptor by triadin and calsequestrin. Biochemistry 37:12987–12993.
doi:10.1021/bi972803d
104. Olojo RO, Hernandez-Ochoa EO, Ikemoto N, Schneider MF (2011) Effects
of conformational peptide probe DP4 on bidirectional signaling between
DHPR and RyR1 calcium channels in voltage-clamped skeletal muscle fibers.
Biophys J 100:2367–2377. doi:10.1016/j.bpj.2011.04.012
105. Pallone TL, Khurana S, Cao C (2012) Voltage-Gated Calcium Channels: Structure
and Function (CACNA). Springer Science, City
106. Pastore A, Piemonte F (2012) S-Glutathionylation signaling in cell biology:
progress and prospects. Eur J Pharm Sci 46:279–292. doi:10.1016/j.ejps.
2012.03.010
107. Pietri-Rouxel F, Gentil C, Vassilopoulos S, Baas D, Mouisel E, Ferry A, Vignaud
A, Hourde C, Marty I, Schaeffer L et al (2010) DHPR alpha1S subunit controls
skeletal muscle mass and morphogenesis. EMBO J 29:643–654. doi:10.1038/
emboj.2009.366
108. Popova OB, Baker MR, Tran TP, Le T, Serysheva II (2012) Identification of
ATP-binding regions in the RyR1 Ca(2)(+) release channel. PLoS One 7:
e48725. doi:10.1371/journal.pone.0048725
109. Porta M, Diaz-Sylvester PL, Neumann JT, Escobar AL, Fleischer S, Copello JA
(2012) Coupled gating of skeletal muscle ryanodine receptors is modulated
by Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol 303:C682–C697.
doi:10.1152/ajpcell.00150.2012
110. Porter Moore C, Zhang JZ, Hamilton SL (1999) A role for cysteine 3635 of RYR1
in redox modulation and calmodulin binding. J Biol Chem 274:36831–36834
111. Radak Z, Zhao Z, Koltai E, Ohno H, Atalay M (2013) Oxygen consumption
and usage during physical exercise: the balance between oxidative stress
and ROS-dependent adaptive signaling. Antioxid Redox Signal 18:1208–1246.
doi:10.1089/ars.2011.4498
112. Rebbeck RT, Karunasekara Y, Gallant EM, Board PG, Beard NA, Casarotto MG,
Dulhunty AF (2011) The beta(1a) subunit of the skeletal DHPR binds to
skeletal RyR1 and activates the channel via its 35-residue C-terminal tail.
Biophys J 100:922–930. doi:10.1016/j.bpj.2011.01.022
113. Reid MB (2001) Nitric oxide, reactive oxygen species, and skeletal muscle
contraction. Med Sci Sports Exerc 33:371–376
114. Reiken S, Lacampagne A, Zhou H, Kherani A, Lehnart SE, Ward C, Huang F,
Gaburjakova M, Gaburjakova J, Rosemblit N et al (2003) PKA phosphorylation
activates the calcium release channel (ryanodine receptor) in skeletal muscle:
defective regulation in heart failure. J Cell Biol 160:919–928. doi:10.1083/jcb.
200211012
115. Rendu J, Brocard J, Denarier E, Monnier N, Pietri-Rouxel F, Beley C, Roux-Buisson
N, Gilbert-Dussardier B, Perez MJ, Romero N et al (2013) Exon skipping
as a therapeutic strategy applied to an RYR1 mutation with pseudo-
exon inclusion causing a severe core myopathy. Hum Gene Ther 24:
702–713. doi:10.1089/hum.2013.052
116. Robin G, Allard B (2012) Dihydropyridine receptors actively control gating of
ryanodine receptors in resting mouse skeletal muscle fibres. J Physiol 590:
6027–6036. doi:10.1113/jphysiol.2012.237321
117. Rodney GG, Moore CP, Williams BY, Zhang JZ, Krol J, Pedersen SE, Hamilton
SL (2001) Calcium binding to calmodulin leads to an N-terminal shift in
its binding site on the ryanodine Receptor. J Biol Chem 276:2069–2074.
doi:10.1074/jbc.M008891200
118. Romero NB, Monnier N, Viollet L, Cortey A, Chevallay M, Leroy JP, Lunardi J,
Fardeau M (2003) Dominant and recessive central core disease associated
with RYR1 mutations and fetal akinesia. Brain 126:2341–2349. doi:10.1093/
brain/awg244
119. Rossi AE, Boncompagni S, Dirksen RT (2009) Sarcoplasmic reticulum-
mitochondrial symbiosis: bidirectional signaling in skeletal muscle. Exerc
Sport Sci Rev 37:29–35. doi:10.1097/JES.0b013e3181911fa4
120. Rossi D, Bencini C, Maritati M, Benini F, Lorenzini S, Pierantozzi E, Scarcella
AM, Paolini C, Protasi F, Sorrentino V (2014) Distinct regions of triadin are
required for targeting and retention at the junctional domain of the
sarcoplasmic reticulum. Biochem J 458:407–417. doi:10.1042/BJ20130719
121. Ruehr ML, Russell MA, Ferguson DG, Bhat M, Ma J, Damron DS, Scott JD, Bond M
(2003) Targeting of protein kinase A by muscle A kinase-anchoring protein
(mAKAP) regulates phosphorylation and function of the skeletal muscle
ryanodine receptor. J Biol Chem 278:24831–24836. doi:10.1074/jbc.M213279200
122. Sakuma K, Yamaguchi A (2010) The functional role of calcineurin in
hypertrophy, regeneration, and disorders of skeletal muscle. J Biomed
Biotechnol 2010:721219. doi:10.1155/2010/721219
123. Sakuma K, Nishikawa J, Nakao R, Watanabe K, Totsuka T, Nakano H, Sano M,
Yasuhara M (2003) Calcineurin is a potent regulator for skeletal muscle
regeneration by association with NFATc1 and GATA-2. Acta Neuropathol
105:271–280. doi:10.1007/s00401-002-0647-0
124. Samso M, Feng W, Pessah IN, Allen PD (2009) Coordinated movement of
cytoplasmic and transmembrane domains of RyR1 upon gating. PLoS Biol 7:
e85. doi:10.1371/journal.pbio.1000085
125. Sanmaneechai O, Likasitwattanakul S, Sangruchi T, Nishino I (2015)
Ophthalmoplegia in congenital neuromuscular disease with uniform
type 1 fiber. Brain Dev 37:459–462. doi:10.1016/j.braindev.2014.07.009
126. Sato I, Wu S, Ibarra MC, Hayashi YK, Fujita H, Tojo M, Oh SJ, Nonaka I,
Noguchi S, Nishino I (2008) Congenital neuromuscular disease with uniform
type 1 fiber and RYR1 mutation. Neurology 70:114–122. doi:10.1212/01.wnl.
0000269792.63927.86
127. Scacheri PC, Hoffman EP, Fratkin JD, Semino-Mora C, Senchak A, Davis MR,
Laing NG, Vedanarayanan V, Subramony SH (2000) A novel ryanodine receptor
gene mutation causing both cores and rods in congenital myopathy. Neurology
55:1689–1696
128. Schrier SA, Falk MJ (2011) Mitochondrial disorders and the eye. Curr Opin
Ophthalmol 22:325–331. doi:10.1097/ICU.0b013e328349419d
129. Sencer S, Papineni RV, Halling DB, Pate P, Krol J, Zhang JZ, Hamilton SL (2001)
Coupling of RYR1 and L-type calcium channels via calmodulin binding
domains. J Biol Chem 276:38237–38241. doi:10.1074/jbc.C100416200
130. Shaaban S, Ramos-Platt L, Gilles FH, Chan WM, Andrews C, De Girolami U,
Demer J, Engle EC (2013) RYR1 mutations as a cause of ophthalmoplegia,
facial weakness, and malignant hyperthermia. JAMA Ophthalmol 131:
1532–1540. doi:10.1001/jamaophthalmol.2013.4392
131. Shen X, Franzini-Armstrong C, Lopez JR, Jones LR, Kobayashi YM, Wang Y,
Kerrick WG, Caswell AH, Potter JD, Miller T et al (2007) Triadins modulate
intracellular Ca(2+) homeostasis but are not essential for excitation-
contraction coupling in skeletal muscle. J Biol Chem 282:37864–37874.
doi:10.1074/jbc.M705702200
132. Shin DW, Pan Z, Kim EK, Lee JM, Bhat MB, Parness J, Kim DH, Ma J (2003) A
retrograde signal from calsequestrin for the regulation of store-operated Ca2+
entry in skeletal muscle. J Biol Chem 278:3286–3292. doi:10.1074/jbc.M209045200
133. Shiva S, Darley-Usmar VM (2003) Control of the nitric oxide-cytochrome c
oxidase signaling pathway under pathological and physiological conditions.
IUBMB Life 55:585–590. doi:10.1080/152165430310001640489
134. Sivitz WI, Yorek MA (2010) Mitochondrial dysfunction in diabetes: from molecular
mechanisms to functional significance and therapeutic opportunities. Antioxid
Redox Signal 12:537–577. doi:10.1089/ars.2009.2531
135. Stamler JS, Hess DT (2010) Nascent nitrosylases. Nat Cell Biol 12:1024–1026.
doi:10.1038/ncb1110-1024
136. Stamler JS, Meissner G (2001) Physiology of nitric oxide in skeletal muscle.
Physiol Rev 81:209–237
137. Stamler JS, Sun QA, Hess DT (2008) A SNO storm in skeletal muscle.
Cell 133:33–35. doi:10.1016/j.cell.2008.03.013
138. Su Z, Blazing MA, Fan D, George SE (1995) The calmodulin-nitric oxide synthase
interaction. Critical role of the calmodulin latch domain in enzyme activation.
J Biol Chem 270:29117–29122
139. Suhr F, Gehlert S, Grau M, Bloch W (2013) Skeletal muscle function during
exercise-fine-tuning of diverse subsystems by nitric oxide. Int J Mol Sci 14:
7109–7139. doi:10.3390/ijms14047109
140. Sun QA, Hess DT, Nogueira L, Yong S, Bowles DE, Eu J, Laurita KR, Meissner G,
Stamler JS (2011) Oxygen-coupled redox regulation of the skeletal muscle
ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc Natl Acad
Sci U S A 108:16098–16103. doi:10.1073/pnas.1109546108
141. Sun QA, Wang B, Miyagi M, Hess DT, Stamler JS (2013) Oxygen-coupled
redox regulation of the skeletal muscle ryanodine receptor/Ca2+ release
channel (RyR1): sites and nature of oxidative modification. J Biol Chem 288:
22961–22971. doi:10.1074/jbc.M113.480228
142. Szegedi C, Sarkozi S, Herzog A, Jona I, Varsanyi M (1999) Calsequestrin: more
than ‘only’ a luminal Ca2+ buffer inside the sarcoplasmic reticulum. Biochem
J 337(Pt 1):19–22
143. Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S,
Zorzato F (2005) Ryanodine receptor 1 mutations, dysregulation of calcium
homeostasis and neuromuscular disorders. Neuromuscul Disord 15:577–587.
doi:10.1016/j.nmd.2005.06.008
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 19 of 20
144. Treves S, Jungbluth H, Muntoni F, Zorzato F (2008) Congenital muscle
disorders with cores: the ryanodine receptor calcium channel paradigm.
Curr Opin Pharmacol 8:319–326. doi:10.1016/j.coph.2008.01.005
145. Uezumi A, Ikemoto-Uezumi M, Tsuchida K (2014) Roles of nonmyogenic
mesenchymal progenitors in pathogenesis and regeneration of skeletal
muscle. Front Physiol 5:68. doi:10.3389/fphys.2014.00068
146. Vega AV, Ramos-Mondragon R, Calderon-Rivera A, Zarain-Herzberg A, Avila G
(2011) Calcitonin gene-related peptide restores disrupted excitation-contraction
coupling in myotubes expressing central core disease mutations in RyR1.
J Physiol 589:4649–4669. doi:10.1113/jphysiol.2011.210765
147. Venturi E, Galfre E, O’Brien F, Pitt SJ, Bellamy S, Sessions RB, Sitsapesan R (2014)
FKBP12.6 activates RyR1: investigating the amino acid residues critical for
channel modulation. Biophys J 106:824–833. doi:10.1016/j.bpj.2013.12.041
148. Volkers M, Rohde D, Goodman C, Most P (2010) S100A1: a regulator of striated
muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial
function. J Biomed Biotechnol 2010:178614. doi:10.1155/2010/178614
149. Walker KS, Watt PW, Cohen P (2000) Phosphorylation of the skeletal muscle
glycogen-targetting subunit of protein phosphatase 1 in response to adrenaline
in vivo. FEBS Lett 466:121–124
150. Wang J, Maertz NA, Lokua AJ, Kranias EG, Valdivia HH (2001) Regulation of
cardiac ryanodine receptors activity by calsequestrin. Biophys J 80
151. Wehrens XH, Lehnart SE, Reiken S, van der Nagel R, Morales R, Sun J, Cheng
Z, Deng SX, de Windt LJ, Landry DW et al (2005) Enhancing calstabin
binding to ryanodine receptors improves cardiac and skeletal muscle
function in heart failure. Proc Natl Acad Sci U S A 102:9607–9612.
doi:10.1073/pnas.0500353102
152. Wei L, Varsanyi M, Dulhunty AF, Beard NA (2006) The conformation of
calsequestrin determines its ability to regulate skeletal ryanodine receptors.
Biophys J 91:1288–1301. doi:10.1529/biophysj.106.082610
153. Wei L, Gallant EM, Dulhunty AF, Beard NA (2009) Junctin and triadin each
activate skeletal ryanodine receptors but junctin alone mediates functional
interactions with calsequestrin. Int J Biochem Cell Biol 41:2214–2224.
doi:10.1016/j.biocel.2009.04.017
154. Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, Muller CR,
Ndondo A, Cloke V, Cullup T et al (2010) RYR1 mutations are a common
cause of congenital myopathies with central nuclei. Ann Neurol 68:717–726.
doi:10.1002/ana.22119
155. Wu S, Ibarra MC, Malicdan MC, Murayama K, Ichihara Y, Kikuchi H, Nonaka I,
Noguchi S, Hayashi YK, Nishino I (2006) Central core disease is due to
RYR1 mutations in more than 90 % of patients. Brain 129:1470–1480.
doi:10.1093/brain/awl077
156. Zalk R, Clarke OB, des Georges A, Grassucci RA, Reiken S, Mancia F, Hendrickson
WA, Frank J, Marks AR (2015) Structure of a mammalian ryanodine receptor.
Nature 517:44–49. doi:10.1038/nature13950
157. Zhang H, Zhang JZ, Danila CI, Hamilton SL (2003) A noncontiguous, intersubunit
binding site for calmodulin on the skeletal muscle Ca2+ release channel. J Biol
Chem 278:8348–8355. doi:10.1074/jbc.M209565200
158. Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H,
Rose MR, Brockington M et al (2007) Molecular mechanisms and phenotypic
variation in RYR1-related congenital myopathies. Brain 130:2024–2036.
doi:10.1093/brain/awm096
159. Zorzato F, Jungbluth H, Zhou H, Muntoni F, Treves S (2007) Functional
effects of mutations identified in patients with multiminicore disease.
IUBMB Life 59:14–20. doi:10.1080/15216540601187803
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Witherspoon and Meilleur Acta Neuropathologica Communications  (2016) 4:121 Page 20 of 20
